Document:

Griffon Corporation
                       2001 Stock Option Plan, as amended

SECTION 1.  GENERAL PROVISIONS
            ------------------

1.1     Name and General Purpose
        ------------------------

     The name of this plan is the  Griffon  Corporation  2001 Stock  Option Plan
(hereinafter  called  the  "Plan").  The  Plan is  intended  to  enable  Griffon
Corporation  (the "Company") and its  subsidiaries  and affiliates to foster and
promote the  interests of the Company by attracting  and retaining  officers and
employees  of the  Company  who  contribute  to the  Company's  success by their
ability,  ingenuity  and  industry,  to enable such  officers  and  employees to
participate in the long-term  success and growth of the Company by giving them a
proprietary  interest  in the  Company  and to  provide  incentive  compensation
opportunities competitive with those of competing corporations.

1.2      Definitions
         -----------

         a.       "Affiliate" means any person or entity controlled by or under
                   ---------
                  common control with the Company, by virtue of the ownership of
                  voting securities, by contract or otherwise.

         b.       "Board" means the Board of Directors of the Company.
                   -----

         c.       "Change in Control" means a change of control of the Company,
                   -----------------
                  or in any person directly or indirectly controlling the
                  Company, which shall mean:

                  (a) a change in control as such term is presently defined in
                  Regulation 240.12b-(f) under the Securities Exchange Act of
                  1934, as amended (the "Exchange Act"); or

                  (b) if any "person" (as such term is used in Section 13(d) and
                  14(d) of the Exchange Act) other than the Company or any
                  "person" who on the date of this Plan is a director or officer
                  of the Company, becomes the "beneficial owner" (as defined in
                  Rule 13(d)-3 under the Exchange Act) directly or indirectly,
                  of securities of the Company representing ten percent (10%) or
                  more of the voting power of the Company's then outstanding
                  securities; or

                  (c) if during the term of the Plan, individuals who at the
                  effective date of the Plan constitute the board of directors,
                  cease for any reason to constitute at least a majority of the
                  board of directors.

         d.       "Code" means the Internal Revenue Code of 1986, as amended.
                   ----

         e.       "Committee" means the Committee referred to in Section 1.3 of
                   ---------
                   the Plan.

         f.       "Common Stock" means shares of the Common Stock, par value
                   ------------
                  $.25 per share, of the Company.

         g.       "Company" means Griffon Corporation, a corporation organized
                   -------
                  under the laws of the State of Delaware (or any successor
                  corporation).

<PAGE>

         h.       "Fair Market Value" means the market price of the Common Stock
                   -----------------
                  on the New York Stock Exchange consolidated reporting system
                  on the date of the grant or on any other date on which the
                  Common Stock is to be valued hereunder. If no sale shall have
                  been reported on the New York Stock Exchange consolidated
                  reporting system on such date, Fair Market Value shall be
                  determined by the Committee in accordance with the Treasury
                  Regulations applicable to incentive stock options under
                  Section 422 of the Code.

         i        "Incentive Stock Option" means an Incentive Stock Option as
                   ----------------------
                  described in Section 2.1 of the Plan.

         j.       "Non-Employee Director" shall have the meaning set forth in
                   ---------------------
                  Rule 16b-3 promulgated by the Securities and Exchange
                  Commission ("Commission"); provided, that such person is also
                  an "outside director" as set forth in Section 162(m) of the
                  Code and the regulations promulgated thereunder.

         k.       "Non-Qualified Stock Option" means a Non-Qualified Stock
                   --------------------------
                  Option as described in Section 2.1 of the Plan.

         l.       "Option" means any option to purchase Common Stock under
                   ------
                  Section 2 of the Plan.

         m.       "Option Agreement" means the option agreement described in
                   ----------------
                  Section 2.5 of the Plan.

         n.       "Participant" means any officer or employee of the Company, a
                   -----------
                  Subsidiary or an Affiliate on the date of grant who is
                  selected by the Committee to participate in the Plan.

         o.       "Subsidiary" means any corporation in which the Company
                   ----------
                  possesses, directly or indirectly, 50% or more of the combined
                  voting power of all classes of stock of such corporation.

         p.       "Total Disability" means accidental bodily injury or sickness
                   ----------------
                  which wholly and continuously disabled an optionee. The
                  Committee, whose decisions shall be final, shall make a
                  determination of Total Disability.

1.3      Administration of the Plan
         --------------------------

     The Plan shall be administered  by the Board or by the Committee  appointed
by the Board consisting of two or more members of the Board all of whom shall be
Non-Employee  Directors.  The Committee shall serve at the pleasure of the Board
and shall have such powers as the Board may, from time to time, confer upon it.

     Subject to this  Section 1.3,  the  Committee  shall have sole and complete
authority to adopt, alter, amend or revoke such administrative rules, guidelines
and  practices  governing  the  operation of the Plan as it shall,  from time to
time, deem advisable, and to interpret the terms and provisions of the Plan.

<PAGE>

     The Committee  shall keep minutes of its meetings and of action taken by it
without a meeting.  A majority of the Committee shall  constitute a quorum,  and
the acts of a majority of the  members  present at any meeting at which a quorum
is present,  or acts  approved in writing by all of the members of the Committee
without a meeting, shall constitute the acts of the Committee.

1.4      Eligibility
         -----------

     Stock  Options may be granted  only to officers or employees of the Company
or a Subsidiary  or Affiliate.  All  employees  are eligible to receive  Options
under the Plan.  Subject to Section  2.3,  any person who has been  granted  any
Option may, if he is  otherwise  eligible,  be granted an  additional  Option or
Options.

1.5      Shares
         ------

     The aggregate  number of shares reserved for issuance  pursuant to the Plan
shall be 1,375,000  shares of Common Stock,  or the number and kind of shares of
stock or other securities which shall be substituted for such shares or to which
such shares shall be adjusted as provided in Section 1.6. No  individual  may be
granted  options to purchase more than an aggregate of 500,000  shares of Common
Stock pursuant to the Plan.

     Such number of shares may be set aside out of the  authorized  but unissued
shares of Common Stock or out of issued shares of Common Stock  acquired for and
held in the Treasury of the Company, not reserved for any other purpose.  Shares
subject to, but not sold or issued under, any Option terminating or expiring for
any reason  prior to its  exercise in full will again be  available  for Options
thereafter granted during the balance of the term of the Plan.

1.6      Adjustments Due to Stock Splits,  Mergers, Consolidation, Etc.
         --------------------------------------------------------------

     If, at any time,  the  Company  shall  take any  action,  whether  by stock
dividend,  stock split,  combination of shares or otherwise,  which results in a
proportionate  increase  or  decrease  in the  number of shares of Common  Stock
theretofore issued and outstanding,  the number of shares which are reserved for
issuance  under the Plan and the  number  of shares  which,  at such  time,  are
subject to Options shall, to the extent deemed appropriate by the Committee,  be
increased or  decreased  in the same  proportion,  provided,  however,  that the
Company shall not be obligated to issue fractional shares.

     Likewise,  in the event of any change in the  outstanding  shares of Common
Stock by reason of any recapitalization, merger, consolidation,  reorganization,
combination or exchange of shares or other corporate change, the Committee shall
make such substitution or adjustments, if any, as it deems to be appropriate, as
to the number or kind of shares of Common  Stock or other  securities  which are
reserved  for  issuance  under  the  Plan  and the  number  of  shares  or other
securities which, at such time are subject to Options.

     In the  event  of a  Change  in  Control,  at the  option  of the  Board or
Committee,  (a) all  Options  outstanding  on the date of such Change in Control
shall become  immediately  and fully  exercisable,  and (b) an optionee  will be
permitted to surrender for cancellation within sixty (60) days after such Change
in Control any Option or portion of an Option  which was  granted  more than six
(6) months prior to the date of such surrender, to the extent not yet exercised,
and to receive a cash payment in an amount  equal to the excess,  if any, of the
Fair  Market  Value (on the date of  surrender)  of the  shares of Common  Stock
subject  to the  Option  or  portion  thereof  surrendered,  over the  aggregate
purchase price for such shares under the Option.

<PAGE>

1.7      Non-Alienation of Benefits
         --------------------------

     Except as herein  specifically  provided,  no right or unpaid benefit under
the Plan shall be subject to  alienation,  assignment,  pledge or charge and any
attempt to  alienate,  assign,  pledge or charge the same shall be void.  If any
Participant  or other person  entitled to benefits  hereunder  should attempt to
alienate,  assign,  pledge or charge any benefit  hereunder,  then such  benefit
shall, in the discretion of the Committee, cease.

1.8      Withholding or Deduction for Taxes
         ----------------------------------

     If, at any time,  the Company or any  Subsidiary  or Affiliate is required,
under applicable laws and regulations, to withhold, or to make any deduction for
any taxes, or take any other action in connection with any Option exercise,  the
Participant  shall be  required  to pay to the  Company  or such  Subsidiary  or
Affiliate the amount of any taxes required to be withheld,  or, in lieu thereof,
at the option of the Company,  the Company or such  Subsidiary  or Affiliate may
accept a  sufficient  number  of shares  of  Common  Stock to cover  the  amount
required to be withheld.

1.9      Administrative Expenses
         -----------------------

     The entire expense of administering the Plan shall be borne by the Company.

1.10     General Conditions
         ------------------

          a.   The Board or the Committee may, from time to time, amend, suspend
               or terminate any or all of the  provisions of the Plan,  provided
               that, without the Participant's  approval,  no change may be made
               which would prevent an Incentive  Stock Option  granted under the
               Plan from  qualifying as an Incentive  Stock Option under Section
               422 of the Code or result in a  "modification"  of the  Incentive
               Stock Option under Section 424(h) of the Code or otherwise  alter
               or impair any right theretofore  granted to any Participant;  and
               further  provided  that,  without the consent and approval of the
               holders of a majority of the  outstanding  shares of Common Stock
               of the  Company  present at a meeting  at which a quorum  exists,
               neither the Board nor the Committee may make any amendment  which
               (i)  changes  the class of persons  eligible  for  options;  (ii)
               increases  (except as provided under Section 1.6 above) the total
               number of shares or other securities  reserved for issuance under
               the Plan;  (iii)  decreases  the minimum  option prices stated in
               Section   2.2  hereof   (other  than  to  change  the  manner  of
               determining  Fair Market Value to conform to any then  applicable
               provision of the Code or any regulation thereunder); (iv) extends
               the expiration date of the Plan, or the limit on the maximum term
               of Options;  or (v) withdraws the administration of the Plan from
               the Committee consisting of two or more members,  each of whom is
               a Non-Employee Director.

          b.   With  the  consent  of  the  Participant  affected  thereby,  the
               Committee  may  amend or  modify  any  outstanding  Option in any
               manner not  inconsistent  with the terms of the Plan,  including,
               without  limitation,   and  irrespective  of  the  provisions  of
               Sections 2.3(c) and 2.4(b) below, to accelerate the date or dates
               as of which an  installment  of an  Option  becomes  exercisable,
               provided that the  Committee  shall not have the right to reprice
               any outstanding options, either by lowering the exercise price or
               by cancelling and regranting.

<PAGE>

          c.   Nothing  contained in the Plan shall  prohibit the Company or any
               Subsidiary  or  Affiliate  from  establishing   other  additional
               incentive compensation  arrangements for employees of the Company
               or such Subsidiary or Affiliate.

          d.   Nothing  in the Plan  shall be deemed to limit,  in any way,  the
               right of the Company or any  Subsidiary or Affiliate to terminate
               a Participant's employment with the Company or such Subsidiary or
               Affiliate at any time.

          e.   Any  decision  or  action  taken by the  Board  or the  Committee
               arising  out  of  or  in   connection   with  the   construction,
               administration,  interpretation  and  effect of the Plan shall be
               conclusive  and  binding  upon all  Participants  and any  person
               claiming under or through any Participant.

          f.   No member of the Board or of the  Committee  shall be liable  for
               any act or action, whether of commission or omission, (i) by such
               member except in  circumstances  involving  actual bad faith, nor
               (ii) by any other member or by any officer, agent or employee.

1.11     Compliance with Applicable Law
         ------------------------------

     Notwithstanding  any other  provision of the Plan, the Company shall not be
obligated to issue any shares of Common Stock,  or grant any Option with respect
thereto,  unless it is advised by  counsel  of its  selection  that it may do so
without  violation of the  applicable  Federal and State laws  pertaining to the
issuance of  securities  and the Company  may require any stock  certificate  so
issued to bear a legend, may give its transfer agent  instructions  limiting the
transfer  thereof,  and may  take  such  other  steps,  as in its  judgment  are
reasonably required to prevent any such violation.

1.12     Effective Date
         --------------

     The Plan will be adopted on February  7, 2001 if  approved by  stockholders
and shall terminate on February 6, 2011.

Section 2.  OPTION GRANTS
            -------------

2.1      Authority of Committee
         ----------------------

     Subject to the  provisions of the Plan,  the Committee  shall have the sole
and complete  authority to determine (i) the  Participants to whom Options shall
be granted;  (ii) the number of shares to be covered by each  Option;  and (iii)
the  conditions  and  limitations,  if any,  in  addition  to those set forth in
Section 2 applicable to the exercise of an Option, including without limitation,
the nature and duration of the restrictions, if any, to be imposed upon the sale
or other disposition of shares acquired upon exercise of an Option.

     Stock  options  granted  under the Plan may be of two types:  an  incentive
stock  option  ("Incentive  Stock  Option");  and a  non-qualified  stock option
("Non-Qualified Stock Option").

     It is intended that the Incentive  Stock Options  granted  hereunder  shall
constitute incentive stock options within the meaning of Section 422 of the Code
and shall be subject to the tax treatment described in Section 422 of the Code.

<PAGE>

     Anything in the Plan to the contrary  notwithstanding,  no provision of the
Plan  relating to  Incentive  Stock  Options  shall be  interpreted,  amended or
altered,  nor shall any  discretion  or authority  granted  under the Plan be so
exercised,  so as to disqualify  either the Plan or,  without the consent of the
optionee, any Incentive Stock Option under Section 422 of the Code.

     The Committee shall have the authority to grant Incentive Stock Options, or
to grant  Non-Qualified Stock Options, or to grant both types of Options. To the
extent that any Option does not qualify as an Incentive  Stock Option,  in whole
or in part,  it shall  constitute a separate  Non-Qualified  Stock Option to the
extent of such disqualification.

2.2      Option Exercise Price
         ---------------------

     The price of stock purchased upon the exercise of Options granted  pursuant
to the Plan shall be the Fair Market  Value  thereof at the time that the Option
is granted.

     If an employee owns or is deemed to own (by reason of the attribution rules
applicable  under  Section  424(d)  of the Code)  more than 10% of the  combined
voting  power  of  all  classes  of  the  stock  of the  Company  or any  parent
corporation  of the Company or any Subsidiary or Affiliate and an Option granted
to such employee is intended to qualify as an Incentive  Stock Option within the
meaning of Section  422 of the Code,  the  exercise  price shall be no less than
110% of the Fair  Market  Value of the  Common  Stock on the date the  Option is
granted.  The  purchase  price is to be paid in full in cash,  certified or bank
cashier's  check or, at the option of the  Company,  Common  Stock valued at its
Fair Market Value on the date of exercise,  or a combination  thereof,  when the
Option is exercised and stock  certificates  will be delivered only against such
payment.

2.3      Incentive Stock Option Grants
         -----------------------------

     Each Incentive Stock Option will be subject to the following provisions:

          a.   Term of Option
               --------------

               An Incentive Stock Option will be for a term of not more than ten
               years from the date of grant,  except in the case of an  employee
               described  in the second  paragraph of Section 2.2 above in which
               case an  Incentive  Stock  Option  will be for a term of not more
               than five years from the date of the grant.

          b.   Annual Limit
               ------------

               To the extent the aggregate Fair Market Value of the Common Stock
               (determined  as of the date of grant)  with  respect to which any
               options  granted  hereunder  are  intended  to be  designated  as
               Incentive  Stock Options  under the Plan (or any other  incentive
               stock option plan of the Company or any  Subsidiary or Affiliate)
               which may be  exercisable  for the first time by the  optionee in
               any calendar  year exceeds  $100,000,  such options  shall not be
               considered incentive stock options.

<PAGE>

          c.   Exercise
               --------

               The  Committee  shall have the  discretion to determine the terms
               and  conditions  of the vesting of any Stock Option award granted
               under the Plan.

               An  Incentive  Stock  Option  shall  be  exercisable  during  the
               optionee's  lifetime  only  by  the  optionee  and  shall  not be
               exercisable by the optionee  unless,  at all times since the date
               of  grant  and at the  time  of  exercise,  such  optionee  is an
               employee of the Company, any parent corporation of the Company or
               any Subsidiary or Affiliate, except that, upon termination of all
               employment (other than by death,  Total  Disability,  or by Total
               Disability followed by death in the circumstances provided below)
               with the Company,  any parent  corporation of the Company and any
               Subsidiary or  Affiliate,  the optionee may exercise an Incentive
               Stock Option at any time within three months  thereafter but only
               to the  extent  such  Option is  exercisable  on the date of such
               termination.

               Upon  termination  of all  employment  by Total  Disability,  the
               optionee  may  exercise  such options at any time within one year
               thereafter,  but only to the extent such Option is exercisable on
               the date of such termination.

               In the event of the death of an optionee (i) while an employee of
               the  Company,  any  parent  corporation  of  the  Company  or any
               Subsidiary  or  Affiliate,  or (ii)  within  three  months  after
               termination  of all  employment  with  the  Company,  any  parent
               corporation of the Company and any Subsidiary or Affiliate (other
               than for  Total  Disability)  or  (iii)  within  one  year  after
               termination on account of Total Disability of all employment with
               the  Company,  any  parent  corporation  of the  Company  and any
               Subsidiary or Affiliate, such optionee's estate or any person who
               acquires  the  right  to  exercise  such  option  by  bequest  or
               inheritance  or by  reason  of  the  death  of the  optionee  may
               exercise such optionee's  Option at any time within the period of
               one year from the date of death.  In the case of clauses  (i) and
               (iii) above, such Option shall be exercisable in full for all the
               remaining shares covered thereby,  but in the case of clause (ii)
               such  Option  shall  be  exercisable  only to the  extent  it was
               exercisable on the date of such termination.

               Notwithstanding the foregoing  provisions  regarding the exercise
               of an Option in the event of  death,  Total  Disability  or other
               termination  of  employment,  in no  event  shall  an  Option  be
               exercisable  in  whole  or in part  after  the  termination  date
               provided in the Option.

          d.   Transferability
               ---------------

               An  Incentive  Stock Option  granted  under the Plan shall not be
               transferable otherwise than by will or by the laws of descent and
               distribution.

<PAGE>

2.4  Non-Qualified Stock Option Grants
     ---------------------------------

     Each   Non-Qualified   Stock  Option  will  be  subject  to  the  following
provisions:

          a.   Term of Option
               --------------

               A Non-Qualified  Stock Option will be for a term of not more than
               ten years from the date of grant.

          b.   Exercise
               --------

               The exercise of a Non-Qualified  Stock Option shall be subject to
               the same terms and  conditions as provided  under Section  2.3(c)
               above except that (i) upon  termination  of all  employment of an
               optionee with the Company or any  Subsidiary  or Affiliate,  such
               optionee may  exercise  such options at any time within two years
               thereafter,  and (ii) upon termination of all employment by Total
               Disability,  the optionee  may exercise  such options at any time
               within five years thereafter, and (iii) in the event of the death
               of an optionee within five years after  termination on account of
               Total  Disability  of all  employment  with the  Company,  or any
               Subsidiary or Affiliate, such optionee's estate or any person who
               acquires  the  right  to  exercise  such  option  by  bequest  or
               inheritance  or by  reason  of  the  death  of the  optionee  may
               exercise  such  optionee's  option at any time within a period of
               five years from the date of death.

          c.   Transferability
               ---------------

               A  Non-Qualified  Stock  Option  granted  under the Plan shall be
               transferable  in  the  discretion  of  the  committee,  including
               transfers to (1) members of the optionee's  family,  (2) a trust,
               (3) a  family  limited  partnership,  or (4) an  estate  planning
               vehicle primarily for the optionee's family.

2.5      Agreements
         ----------

     In  consideration  of any Options granted to a Participant  under the Plan,
each such  Participant  shall  enter into an Option  Agreement  with the Company
providing,  consistent  with the  Plan,  such  terms as the  Committee  may deem
advisable.<PAGE>
                                                                    Exhibit 10.9

                                LICENSE AGREEMENT

     This LICENSE AGREEMENT (the "Agreement"), dated as of December 18, 2003
(the "Effective Date"), is made by and between Endo Pharmaceuticals Inc., a
Delaware corporation having its principal office at 100 Painters Drive, Chadds
Ford, Pennsylvania 19317 ("Endo"), and EpiCept Corporation, a Delaware
corporation having its principal office at 270 Sylvan Avenue, Englewood Cliffs,
New Jersey 07632 ("EpiCept"). Endo and EpiCept are each sometimes referred to
individually as a "Party" and together as the "Parties."

                                    RECITALS

     WHEREAS, EpiCept is currently developing a topical lidocaine patch product
currently known as LidoPAIN(R) BP for the treatment of acute low back pain and
owns patents covering the use of a topical lidocaine patch product for the
treatment of low back pain;

     WHEREAS, Endo is engaged in the development and marketing of proprietary
pharmaceutical products for the treatment of pain, including a topical lidocaine
patch product; and

     WHEREAS, Endo desires to obtain from EpiCept, and EpiCept desires to grant
to Endo, the exclusive rights in the Territory to the Licensed Products under
certain Patents and other Technology for the commercialization of Licensed
Products (each as defined below).

     NOW, THEREFORE, in consideration of the foregoing premises and the
representations, covenants and agreements contained herein, Endo and EpiCept,
intending to be legally bound, hereby agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS

     When used in this Agreement, whether in the singular or plural, each of the
following capitalized terms shall have the meanings set forth in this Article 1.

     1.1 "Action or Proceeding" shall mean any action, suit, proceeding,
arbitration, Order, inquiry, hearing, assessment with respect to fines or
penalties or litigation (whether civil, criminal, administrative, investigative
or informal) commenced, brought, conducted or heard by or before, or otherwise
involving, any Governmental or Regulatory Authority or other Person.

     1.2 "Affiliate" means a Person that, directly or indirectly, through one or
more intermediates, controls, is controlled by, or is under common control with,
the Person specified, but only for so long as the relationship exists. For the
purposes of this definition, control shall mean the direct or indirect ownership
of (i) in the case of
<PAGE>
corporate entities, securities authorized to cast at least fifty percent (50%)
of the votes in any election for directors, (ii) in the case of non-corporate
entities, at least fifty percent (50%) ownership interest with the power to
direct the management and policies of such non-corporate entity, or (iii) such
lesser percentage as may be the maximum percentage allowed to be owned by a
foreign corporation under the applicable laws or regulations of a particular
jurisdiction outside of the United States) of the equity having the power to
vote in the election of directors or to direct the management and policies of
another entity. Notwithstanding the foregoing, the term "Affiliate" shall not
include subsidiaries in which a Person or its Affiliates owns a majority of the
ordinary voting power to elect a majority of the board of directors, but is
restricted from electing such majority by contract or otherwise, until such time
as such restriction is no longer in effect.

     1.3 "Applicable Laws" shall mean all laws (including common law), treaties,
statutes, ordinances, rules, regulations, Orders, permits, directives, plans,
codes, interpretations, notice and demand letters, prohibitions, obligations,
schedules, timetables, standards, conditions and requirements of any
Governmental or Regulatory Authority, as may be in effect from time to time,
that relate to the Licensed Products or the Licensed Intellectual Property.

     1.4 "Breach Notice" has the meaning set forth in Section 9.2.

     1.5 "Breaching Party" has the meaning set forth in Section 9.2.

     1.6 "Business Day" means any day except Saturday and Sunday, on which
commercial banking institutions in New York are open for business. Any other
reference in this Agreement to "day" whether or not capitalized shall refer to a
calendar day, not a Business Day.

     1.7 "Commercially Reasonable Efforts" means, with respect to a Party, the
efforts and resources which would be used by that Party consistent with
prevailing pharmaceutical industry standards for a company of similar size and
scope to such Party with respect to a product or potential product at a similar
stage in its development or product life and of similar market potential taking
into account efficacy, safety, the anticipated Regulatory Authority approved
labeling, the competitiveness of alternative products in the market place or
under development, the patent and other proprietary position of the product, the
likelihood of Regulatory Approval, the commercial value of the product and other
relevant factors.

     1.8 "Confidential Information" means all secret, confidential or
proprietary information or data, whether provided in written, oral, graphic,
video, computer or other form, provided by one Party (the "Disclosing Party") to
the other Party (the "Receiving Party") pursuant to this Agreement or generated
pursuant to this Agreement, including but not limited to, information relating
to the Disclosing Party's existing or proposed research, development efforts,
patent applications, business or products and any other materials that have not
been made available by the Disclosing Party to the general public. The terms of
this Agreement shall also be deemed Confidential Information hereunder,

                                       -2-
<PAGE>
except to the extent disclosed pursuant to Section 7.5 herein. Notwithstanding
the foregoing sentences, Confidential Information shall not include any
information or materials that:

          (a) were already known to the Receiving Party (other than under an
obligation of confidentiality known to the Receiving Party), at the time of
disclosure by the Disclosing Party to the extent such Receiving Party has
documentary evidence to that effect;

          (b) were generally available to the public or otherwise part of the
public domain at the time of its disclosure to the Receiving Party;

          (c) became generally available to the public or otherwise part of the
public domain after its disclosure or development, as the case may be, and other
than through any act or omission of a Party in breach of such Party's
confidentiality obligations under this Agreement;

          (d) were subsequently lawfully disclosed to the Receiving Party by a
Third Party who, to the Knowledge of the Receiving Party, had no obligation to
the Disclosing Party not to disclose such information to others;

          (e) were independently discovered or developed by or on behalf of the
Receiving Party without the use of the Confidential Information belonging to the
Disclosing Party and the Receiving Party has documentary evidence to that
effect; or

          (f) is approved for release by the Disclosing Party in writing.

     1.9 "Control," "Controls," "Controller" or "Controlled" means with respect
to Technology and/or patent rights, the ownership thereof, or the possession of
the ability to grant licenses or sublicenses thereto without violating the terms
of any agreement or other arrangement with, or the rights of, any Third Party
existing as of the date on which such license or sublicense is granted.

     1.10 "Disclosing Party" has the meaning set forth in Section 1.8.

     1.11 "Endo Baseline Sales" ***

     1.12 "Endo BP Product" means a non-sterile adhesive backed topical patch,
for sale by prescription only, containing lidocaine as the only active
ingredient, indicated, and approved by the FDA, for treating chronic low back
pain (or a substantially similar indication), and which indication is covered by
a Valid Claim of the EpiCept Licensed Patents.

     1.13 "Endo Inventions" has the meaning set forth in Section 10.1(b).

                                       -3-
<PAGE>
     1.14 "EpiCept Improvements" means any and all Patent rights or Technology
Controlled by EpiCept arising after the Effective Date that claim an
improvement, enhancement, invention or modification relating to a Licensed
Product.

     1.15 "EpiCept Intellectual Property" means the EpiCept Technology, EpiCept
Trademarks, EpiCept Improvements and EpiCept Licensed Patents.

     1.16 "EpiCept Licensed Patents" means the Patent rights Controlled by
EpiCept as of the Effective Date necessary to make, have made, use, sell offer
for sale or import Licensed Products recited in Schedule 1.16 and the foreign
counterparts thereof, and any Patent rights included in the EpiCept
Improvements.

     1.17 "EpiCept Product Registration Data" means (i) all regulatory files
relating thereto, including, but not limited to, any licenses (to the extent
transferable), and minutes of meetings and telephone conferences with the FDA,
validation data, preclinical and clinical studies and tests related to the
Product including original data, case report forms, study files relating to the
aforementioned studies and tests, and all audit reports of clinical studies,
plus all investigational new drug applications and amendments, annual reports
and safety reports associated therewith, drug master files, as well as any
foreign equivalents of any of the foregoing, which are in EpiCept's or its
Affiliates' possession or control, and all correspondence with the FDA regarding
the marketing status of the Product; and (ii) all records maintained under
current Good Manufacturing Practices ("GMPs") or other record keeping or
reporting requirements of the FDA, the Environmental Protection Agency, the
Occupational Safety and Health Administration or any other United States or
foreign regulatory authorities, including, but not limited to, FDA warning
letters, FDA Notices of Adverse Finding Letters, FDA audit reports (including
any comments on such reports), all other correspondence and communications with
regulatory agencies in connection with the Product (including any advertising
and promotion documents and 2253 forms), adverse event files, complaint files,
manufacturing records; as well as any foreign equivalents of any of the
foregoing which are in EpiCept's or its Affiliates' possession or Control.

     1.18 "EpiCept Technology" means any and all Technology Controlled by
EpiCept as of the Effective Date and any Technology included in the EpiCept
Improvements.

     1.19 "EpiCept Third Party Consent(s)" has the meaning set forth in Section
6.2(c).

     1.20 "EpiCept Trademarks" means the trademarks set forth on Schedule 1.20,
including all applications, renewals, registrations and common law rights
therefor, together with all documentation associated therewith, including any
prior right agreements or consent letters pertaining thereto, and any
distinctive trade dress, logos and service marks owned by Seller and used solely
in connection with the Product, each as set forth on Schedule 1.20.

                                       -4-
<PAGE>
     1.21 "FDA" means the United States Food and Drug Administration, or any
successor agency thereof.

     1.22 "Final Regulatory Approval" means Regulatory Approval that allows for
the immediate marketing and sale of a Licensed Product.

     1.23 "First Commercial Sale" means the first sale by Endo or its Affiliates
or sublicensees of a Licensed Product to a Third Party for end use or
consumption of such Licensed Product in the Territory after a Regulatory
Authority in the Territory has granted Final Regulatory Approval of such
Licensed Product.

     1.24 "Force Majeure" means any occurrence beyond the reasonable control of
a Party that prevents or substantially interferes with the performance by the
Party of any of its obligations hereunder, if such occurs by reason of any act
of God, flood, fire, explosion, earthquake, strike, lockout, labor dispute,
casualty or accident; or war, revolution, civil commotion, acts of public
enemies, terrorist attack, blockage or embargo; or any injunction, law, order,
proclamation, regulation, ordinance, demand or requirement of any government (to
the extent such government has ruling authority over such Party) or of any
subdivision, authority or representative of any such government; or other
similar event, beyond the reasonable control of such Party, if and only if the
Party affected shall have used reasonable efforts to avoid such occurrence.

     1.25 "GAAP" means accounting principles generally acceptable in the United
States.

     1.26 "Governmental or Regulatory Authority" means (a) the United States of
America, (b) any state, commonwealth, territory or possession of the United
States of America and any political subdivision thereof (including counties,
cities, municipalities, provinces and parishes), (c) any foreign (as to the
United States of America) sovereign entity and any political subdivision
thereof, and (d) any court, tribunal, department, board, bureau, arbitrator,
authority, quasi-governmental authority, agency, commission, official or other
instrumentality of any of the foregoing.

     1.27 "IND" means an Investigational New Drug Application, as defined in the
U.S. Federal Food, Drug, and Cosmetic Act, pursuant to 21 C.F.R. Section 312.3
as amended, and the regulations promulgated thereunder, or the equivalent
thereto as specified in any succeeding legislation, and all supplements and
amendments that may be filed with respect to the foregoing.

     1.28 "Indemnitee" has the meaning set forth in Section 8.3(a).

     1.29 "Indemnitor" has the meaning set forth in Section 8.3(a).

     1.30 "Independent Sublicensees" has the meaning set forth in Section 9.4.

     1.31 "Infringement Notice" has the meaning set forth in Section 10.7(a).

                                       -5-
<PAGE>
     1.32 "Knowledge" shall mean, with respect to any Party, that which the
management personnel (or individuals performing similar functions) of such Party
or other individuals with primary or supervisory responsibility for or daily
involvement with the business of such Party knows or should reasonably be
expected to know.

     1.33 "Licensed Products" means, collectively, the Endo BP Product and the
LidoPAIN(R) BP Product.

     1.34 "LidoPAIN(R) BP Product" means a non-sterile adhesive backed topical
patch, for sale by prescription only, containing lidocaine as the only active
ingredient and indicated, and approved by the FDA, for the treatment of acute
low back pain (or a substantially similar indication).

     1.35 "Lien or Other Encumbrance" shall mean, with respect to any asset, any
mortgage, lien, pledge, security interest, claim, charge, option, right of first
refusal or other encumbrance, restriction or limitation of any kind in respect
of such asset.

     1.36 "Losses" has the meaning set forth in Section 8.1.

     1.37 "Marketing Partner" means a Third Party with a reasonable marketing
presence in any country outside the North American Territory, as applicable,
that is competent and reputable in the industry of pharmaceutical sales and
distribution in such country.

     1.38 "Milestone Payments" has the meaning set forth in Section 4.2.

     1.39 "NDA" means a New Drug Application pursuant to 21 U.S.C. Section
505(b)(1) or Section 505(b)(2), or supplement thereto, submitted to the FDA or
any successor application or procedure required for Regulatory Approval to
commence sale of a Licensed Product.

     1.40 "NDA Acceptance" means the written notification by the FDA that the
NDA has met all the criteria for filing acceptance pursuant to 21 C.F.R. Section
314.101.

     1.41 "Net Sales" means the gross amounts invoiced by Endo, any of its
Affiliates and/or any of its sublicensees on account of sales of Licensed
Products to Third Parties (including without limitation Third Party distributors
and wholesalers), less the total of the following deductions from such gross
amounts which are actually incurred, allowed, accrued or specifically allocated:

          (a) Trade, cash and/or quantity discounts actually allowed or accrued
which are not already reflected in the amount invoiced;

          (b) Excise, sales and other consumption taxes and custom duties to the
extent included in the invoice price and to the extent such taxes are remitted
to the applicable taxing authority;

                                       -6-
<PAGE>
          (c) Freight, insurance and other transportation charges to the extent
included in the invoice price and separately identified on the invoice or other
documentation maintained in the ordinary course of business;

          (d) Amounts repaid, credited or accrued by reason of returns,
rejections, defects or recalls or because of chargebacks, retroactive price
reductions, refunds or billing errors;

          (e) ***

          (f) Payments and rebates directly related to the sale of Licensed
Products accrued, paid or deducted in a manner consistent with GAAP, pursuant to
agreements (including, but not limited to, managed care agreements) with Third
Parties or any Governmental or Regulatory Authority; and

          (g) Any other similar and customary deductions taken in accordance
with GAAP consistently applied.

No deductions shall be made for commissions paid to any Person who is regularly
employed by the seller of a Licensed Product on its payroll. Use of Licensed
Products for promotional, sampling or compassionate use purposes or for use in
clinical trials contemplated under this Agreement shall not be considered in
determining Net Sales. In the case of any sale of a Licensed Product between the
Parties and their respective Affiliates or sublicensees for resale, Net Sales
shall be calculated as above only on the first arm's length sale thereafter to a
Third Party.

     1.42 "Non-Breaching Party" has the meaning set forth in Section 9.2.

     1.43 "North American Territory" means the United States, Canada and Mexico,
and their respective territories, provinces and protectorates.

     1.44 "Order" shall mean any writ, judgment, decree, injunction, ruling or
similar order of any Governmental or Regulatory Authority (in each such case
whether preliminary or final).

     1.45 "Patents" means patents and patent applications and any and all
extensions, renewals, continuations, continuations-in-part, divisions, reissues,
re-examination certificates or foreign counterparts of any of the foregoing.

     1.46 "Person" or "person" means any individual, firm, corporation,
partnership, limited liability company, trust, unincorporated organization or
other entity or a government agency or political subdivision thereto, and shall
include any successor (by merger or otherwise) of such Person.

     1.47 "Prosecution" means the preparation, filing, prosecution, issuance and
maintenance (including, without limitation, interference, opposition and similar
third

                                       -7-
<PAGE>
party proceedings before the relevant patent office) of any patent applications
and patents in EpiCept Licensed Patents.

     1.48 "Receiving Party" has the meaning set forth in Section 1.8.

     1.49 "Regulatory Approval" means the technical, medical and scientific
licenses, registrations, authorizations and approvals (including, without
limitation, approvals of NDAs, supplements and amendments, pre- and post-
approvals, pricing and Third Party reimbursement approvals, and labeling
approvals) of any national, supra-national, regional, state or local regulatory
agency, department, bureau, commission, council or other governmental entity in
the Territory, necessary for the development (including the conduct of clinical
trials), manufacture, distribution, marketing, promotion, offer for sale, use,
import, reimbursement, export or sale of a Licensed Product in a regulatory
jurisdiction.

     1.50 "Regulatory Authority" means any national (e.g., the FDA),
supra-national, regional, state or local regulatory agency, department, bureau,
commission, council or other governmental entity involved in the granting of
Regulatory Approval in any country in the Territory.

     1.51 "Royalties" has the meaning set forth in Section 5.1.

     1.52 "Royalty Term" has the meaning set forth in Section 5.2.

     1.53 "Serious Adverse Drug Experience" means any of an "adverse drug
experience," a "life-threatening adverse drug experience," a "serious adverse
drug experience," or an "unexpected adverse drug experience," as those terms are
defined at either 21 C.F.R. Section 312.32 or 21 C.F.R. Section 314.80 or
relevant foreign regulation within the Territory.

     1.54 "Supply Agreement" means that certain supply agreement to be entered
into by the Parties in the future (but in any event within *** after the date on
which EpiCept has filed the NDA for the LidoPAIN(R) BP Product or such other
date as may be mutually agreed upon by the Parties), which agreement provides
for the supply of the LidoPAIN(R) BP Product by EpiCept to Endo on commercially
reasonable terms and conditions, as further set forth in Section 3.9.

     1.55 "Technology" means any and all information and materials, including
but not limited to, any and all compounds, equipment, specifications, designs,
formulae, methods, techniques, processes, procedures, inventions, know-how, data
and information, documentation and other technology, whether or not patentable
or protectible as a trade secret, that is necessary to use, market or sell a
Licensed Product and develop the Endo BP Product.

     1.56 "Term" has the meaning set forth in Section 9.1.

                                       -8-
<PAGE>
     1.57 "Territory" means worldwide.

     1.58 "Third Party(ies)" means any Person other than EpiCept, Endo and their
respective Affiliates.

     1.59 "Third Party Claim" has the meaning set forth in Section 8.1.

     1.60 "Valid Claim" means a claim of an issued and unexpired patent, or a
claim of a pending patent application or a supplementary protection certificate,
which claim has not been held invalid or unenforceable by a court or other
government agency of competent jurisdiction from which no appeal can be or has
been taken and has not been held or admitted to be invalid or unenforceable
through re-examination or disclaimer, opposition procedure, nullity suit or
otherwise, which claim, but for the licenses granted herein, would be infringed
by the sale of a Licensed Product; provided, however, that if a claim of a
pending patent application shall not have issued within five (5) years after the
filing date from which such claim takes priority such claim shall not constitute
a Valid Claim for the purposes of this Agreement unless and until such claim
shall issue.

     1.61 "Withholding Taxes" has the meaning set forth in Section 5.4.

                                    ARTICLE 2
                            LICENSES AND EXCLUSIVITY

     2.1 License Grant. Subject to Section 2.5 herein, EpiCept hereby grants to
Endo a royalty-bearing, exclusive (even as to EpiCept and its Affiliates) right
and license, with the right to grant sublicenses (subject to Section 2.2) under
the EpiCept Intellectual Property and EpiCept Product Registration Data to (i)
develop, market, use, sell, offer for sale and import the LidoPAIN(R) BP Product
within the Territory and (ii) develop, make, have made, manufacture, market,
use, sell, offer for sale and import the Endo BP Product in the Territory. For
the avoidance of doubt, this Agreement does not grant Endo any right to make or
have made the LidoPAIN(R) BP Product nor grant EpiCept any rights whatsoever to
any Endo product, including the Lidoderm(R) and the Endo BP Product.

     2.2 Use of Affiliates, Sublicensees and Subcontractors. The licenses
granted under Section 2.1 include the right of Endo to grant sublicenses to its
Affiliates and other third parties, provided that Endo gives EpiCept advance
written notice of any sublicenses and a reasonable opportunity to comment on the
identity of such sublicensee and that Endo takes into consideration EpiCept's
reasonable comments with respect thereto. Endo acknowledges that the grant of a
sublicense shall not relieve Endo from its obligations under this Agreement, and
each sublicensee shall be bound by all of the terms and conditions of this
Agreement applicable to Endo. Endo shall be responsible for the compliance of
its Affiliates and sublicensees with this Agreement. Endo shall provide EpiCept
with a copy of each such sublicense agreement within thirty (30) days of its
execution, provided that Endo may redact elements of same that do not relate to
Endo's obligations to EpiCept hereunder, including, but not limited to,
financial terms.

                                       -9-
<PAGE>
     2.3 Exclusivity. During the Term, neither EpiCept nor its Affiliates shall,
either itself or with a Third Party, (a) develop, attempt to develop, actively
investigate, commercialize or sell a Licensed Product or any other prescription
lidocaine-containing topical patch product for the treatment of pain in the
Territory, or (b) submit or reopen an IND for the LidoPAIN(R) BP Product, except
that EpiCept may do any of the foregoing in order to fulfill its obligations
under this Agreement. Notwithstanding (a) above, EpiCept shall have the right to
develop or commercialize, by itself or with Third Parties, any
lidocaine-containing over-the-counter products, prescription
lidocaine-containing sterile topical hydrogel patch products indicated for, but
not limited to, the treatment of surgical, incisional pain and
lidocaine-containing topical patch products for the treatment of tinnitus and
vertigo.

     2.4 No Implied Licenses. Only the licenses expressly granted herein shall
be of legal force and effect. No license rights shall be created hereunder by
implication, estoppel or otherwise. Furthermore, nothing herein shall be
construed as granting any license whatsoever to EpiCept under any Intellectual
Property owned or licensed by Endo.

     2.5 Retained Rights. Subject to the restrictions set forth in Section 2.3
above, EpiCept retains the right to use and/or license others to use the EpiCept
Intellectual Property for every purpose except for those uses specifically
licensed to Endo in Section 2.1 above.

                                    ARTICLE 3
                    DEVELOPMENT, COMMERCIALIZATION AND SUPPLY

     3.1 Development of LidoPAIN(R) BP Product. EpiCept shall be responsible, at
EpiCept's sole cost and expense, for continuing and completing the development,
including, without limitation, the conduct of all clinical trials (and the
supply of clinical product therefor) and the preparation and submission of the
NDA in order to obtain Regulatory Approval for the LidoPAIN(R) BP Product.

     3.2 Development of Endo BP Product. Endo shall be responsible, at Endo's
sole cost and expense, for continuing and completing the development, including,
without limitation, the conduct of all clinical trials (and the supply of
clinical product therefor) and the preparation and submission of the NDA in
order to obtain Regulatory Approval for the Endo BP Product.

     3.3 Diligence.

          (a) By EpiCept. Except as specifically provided herein or as otherwise
mutually agreed upon by the Parties, EpiCept shall be responsible for conducting
all clinical studies and development activities for the LidoPAIN(R) BP Product.
EpiCept shall also be responsible for manufacturing and packaging all clinical
supply of the LidoPAIN(R) BP Product for the clinical studies and development
activities. EpiCept shall use Commercially Reasonable Efforts to develop and
obtain Regulatory

                                      -10-
<PAGE>
Approval for the LidoPAIN(R) BP Product in the Territory. EpiCept shall be
responsible for (a) the preparation of all documents submitted to Regulatory
Authorities and the filing of all submissions relating to Regulatory Approval
for the LidoPAIN(R) BP Product; and (b) all regulatory actions, communications
and meetings with any Regulatory Authority with respect to the LidoPAIN(R) BP
Product. Subject to the foregoing, the Parties shall mutually agree as to which
countries EpiCept will file for Regulatory Approvals of the LidoPAIN(R) BP
Product. In the event the Parties do not agree as to any particular country,
Endo shall make the final determination as to whether Regulatory Approval of the
LidoPAIN(R) BP Product shall be sought in such country and such determination
shall be binding on the Parties; provided that if Endo elects not to seek
Regulatory Approval in any country, the license granted to Endo with respect to
the LidoPAIN(R) BP Product in such country shall revert back to EpiCept and Endo
shall have no commercialization rights with respect to the LidoPAIN(R) BP
Product in such country (other than those rights set forth in Section 3.4); it
being understood by the Parties that in such event, Endo shall continue to have
license rights in the EpiCept Intellectual Property in such country.

          (b) By Endo. Except as specifically provided herein or as otherwise
mutually agreed upon by the Parties, Endo shall be responsible for conducting
all clinical studies, development and commercialization activities for the Endo
BP Product in the North American Territory and all commercialization activities
for the LidoPAIN(R) BP Product in the Territory. Endo shall use Commercially
Reasonable Efforts to develop and commercialize the Endo BP Product in the North
American Territory and to commercialize the LidoPAIN(R) BP Product in the
Territory. Endo shall have sole discretion in determining in which countries it
will file for Regulatory Approvals of the Endo BP Product and in which countries
it will commercialize the Endo BP Product in the Territory. Subject to Section
3.4 herein, Endo shall commercialize the LidoPAIN(R) BP Product in the United
States within six (6) months from the date on which LidoPAIN(R) BP Product
receives Final Regulatory Approval in the United States so long as EpiCept shall
have supplied Endo with quantities of the LidoPAIN(R) BP Product sufficient to
commercially launch the Product as set forth in Endo's committed forecast
delivered pursuant to the Supply Agreement. With respect to those countries
outside the United States in which EpiCept has obtained Final Regulatory
Approval of the LidoPAIN(R) BP Product. Endo shall, either through a Marketing
Partner(s) or on its own, commercialize the LidoPAIN(R) BP Product in each such
country within three (3) years from the date on which LidoPAIN(R) BP receives
Final Regulatory Approval in the United States.

     3.4 Reversion of Rights to EpiCept. LidoPAIN(R) BP. In the event that
EpiCept has obtained Final Regulatory Approval of the LidoPAIN(R) BP Product in
a particular country and Endo fails to commercialize the LidoPAIN(R) BP Product
in such country within three (3) years from the date on which the LidoPAIN(R) BP
Product receives Final Regulatory Approval in the United States (provided that
such period shall be *** months with respect to countries in the North American
Territory and so long as EpiCept shall have supplied Endo with quantities of the
LidoPAIN(R) BP Product sufficient to commercially launch the Product as set
forth in Endo's committed forecast

                                      -11-
<PAGE>
delivered pursuant to the Supply Agreement), then the license granted to Endo by
EpiCept in Section 2.1 above shall terminate with respect to the LidoPAIN(R) BP
Product in such country(ies), and EpiCept shall have the right to commercialize
or license the commercialization rights to the LidoPAIN(R) BP Product in each
such country; provided that EpiCept shall pay Endo a *** royalty on the net
sales of the LidoPAIN(R) BP Product in such country.

     3.5 Reports.

          (a) By EpiCept. Every six (6) months following the Effective Date,
EpiCept shall provide Endo a written report summarizing the efforts and
accomplishments of EpiCept during the preceding six (6) month period in
developing the LidoPAIN(R) BP Product and the development plans for same during
the subsequent six (6) month period. Such reports shall include, without
limitation, summaries of scientific and clinical data obtained in furtherance of
EpiCept's attempts to develop the LidoPAIN(R) BP Product and a showing of
compliance with EpiCept's obligations under Section 3.3(a) above. Endo shall
have the right to provide EpiCept with comments regarding EpiCept's development
plans for the subsequent six (6) month period contained in such reports, and
EpiCept shall take such comments into consideration, provided that EpiCept shall
retain final decision-making authority with respect to any and all such
development plans.

          (b) By Endo. Every six (6) months following the Effective Date, Endo
shall provide EpiCept a written report summarizing the efforts and
accomplishments of Endo, its Affiliates and its sublicensees during the
preceding six (6) month period in developing and commercializing the Endo BP
Product and, after Regulatory Approval has been received for the LidoPAIN(R) BP
Product, in commercializing the LidoPAIN(R) BP Product and their development and
commercialization plans, as applicable, for the subsequent six (6) month period.
Such reports shall include, without limitation, summaries of scientific and
clinical data obtained in furtherance of Endo's attempts to develop and
commercialize Licensed Products as required hereunder and a showing of
compliance with Endo's obligations under Section 3.3(b) above.

     3.6 Regulatory Matters; EpiCept Assistance. All Regulatory Approvals with
respect to the Endo BP Product in the Territory shall be in Endo's or Endo's
designee's name. Endo shall have exclusive control over, and authority and
responsibility for, the regulatory strategies relating to the development and
commercialization of the Endo BP Product in the Territory, including, without
limitation: (a) the preparation of all documents submitted to Regulatory
Authorities and the filing of all submissions relating to Regulatory Approval
for the Endo BP Product; and (b) all regulatory actions, communications and
meetings with any Regulatory Authority with respect to the Endo BP Product. Upon
the request of Endo, EpiCept shall provide to Endo on a timely basis such
information in its possession relating to the LidoPAIN(R) BP Product as may be
required for regulatory activities related to the commercialization of the
LidoPAIN(R) BP Product, and otherwise provide reasonable assistance to Endo in
complying with all regulatory obligations in the Territory, including without
limitation, safety updates,

                                      -12-
<PAGE>
amendments, annual reports, pharmacovigilance filings, investigator
notifications, manufacturing facility inspections and certifications and product
approvals. Endo shall be responsible for interfacing, corresponding and meeting
with all Regulatory Authorities in the Territory with respect to the Endo BP
Product and, after Regulatory Approval has been obtained, the LidoPAIN(R) BP
Product. EpiCept shall cooperate with Endo to provide all reasonable assistance
and take all actions reasonably requested by Endo that are necessary to comply
with any law applicable to any Licensed Product, including, but not limited to,
reporting of adverse drug experience reports (and serious adverse drug
experiences) to Regulatory Authorities in the Territory.

     3.7 Adverse Event Reporting.

          (a) Each Party shall, and shall require its respective Affiliates to:

               (i) to the extent permissible under time constraints and
reporting requirements, provide to the other Party in advance of initial or
periodic submission to Regulatory Authorities any and all adverse event reports
and Serious Adverse Drug Experience reports from clinical trials and commercial
experiences with the LidoPAIN(R) BP Product;

               (ii) provide such adverse event reports and Serious Adverse Drug
Experience reports relating to the LidoPAIN(R) BP Product to the other Party
contemporaneously with the provision of such reports to the applicable
Regulatory Authority; and

               (iii) adhere to all requirements of applicable laws, rules and
regulations which relate to the reporting and investigation of adverse events
and Serious Adverse Drug Experiences and keep the other Party informed of such
events.

          (b) EpiCept shall, and shall require its respective Affiliates to:

               (i) to the extent permissible under time constraints and
reporting requirements, provide to Endo in advance of initial or periodic
submission to Regulatory Authorities any and all adverse event reports and
Serious Adverse Drug Experience reports from clinical trials and commercial
experiences with the Endo BP Product; and

               (ii) provide such adverse event reports and Serious Adverse Drug
Experience reports relating to the Endo BP Product to Endo contemporaneously
with the provision of such reports to the applicable Regulatory Authority.

          (c) If a Party contracts with a Third Party for research to be
performed by such Third Party on any of the Licensed Products, that Party shall
require such Third Party to report to the contracting Party the information set
forth above.

                                      -13-
<PAGE>
     3.8 EpiCept Right to Co-Promote. EpiCept, at its option, shall have the
right to become Endo's co-promotion partner with respect to the LidoPAIN(R) BP
Product as set forth in this Section 3.8. Within thirty (30) days after
EpiCept's first filing of an NDA or the equivalent thereof in any country in the
Territory for the LidoPAIN(R) BP Product, EpiCept shall notify Endo of such
filing in writing (the "NDA Notice"). If such NDA Notice contains reasonably
detailed terms and conditions upon which EpiCept offers to co-promote the
LidoPAIN(R) BP Product in such country, then for a period of up to ***
commencing on the date of the NDA Notice, Endo and EpiCept shall negotiate in
good faith to reach agreement for the co-promotion of the LidoPAIN(R) BP Product
in such country. Unless mutually agreed to by the Parties, no such co-promotion
arrangement shall effect any change to the financial terms of this Agreement,
and, in any such co-promotion arrangement, EpiCept shall be solely responsible
for the costs and expenses of its sales representatives.

     3.9 Commercial Supply of LidoPAIN(R) BP Product. EpiCept shall be
responsible for the manufacture and supply, or to obtain supply, for Endo's
requirements in the Territory of the LidoPAIN(R) BP Product pursuant to a Supply
Agreement to be negotiated in good faith between the Parties after the Effective
Date. The Supply Agreement shall permit EpiCept to engage Third Party
subcontractors to carry out such manufacture and supply on EpiCept's behalf. Any
such supply shall be at EpiCept' s commercially reasonable, fully loaded
manufacturing costs, as documented by EpiCept, which costs shall include
reasonable profit margins set forth in Supply Agreement.

                                    ARTICLE 4
                     INITIAL PAYMENT AND MILESTONE PAYMENTS

     4.1 Initial Payment. Within two (2) Business Days after the Effective Date,
Endo shall pay EpiCept seven million five hundred thousand U.S. Dollars
(US$7,500,000), by wire transfer, to the credit of such bank account as
designated by EpiCept in Schedule 4.1.

     4.2 Milestone Payments. Endo shall pay to EpiCept the following one-time
milestone payments (the "Milestone Payments") within *** days following the
specified events:

***

                                    ARTICLE 5
                                    ROYALTIES

     5.1 Royalty Rate. Subject to the provisions of this Article 5, Endo shall
pay EpiCept *** of the aggregate Net Sales of the LidoPAIN(R)BP Product in the
Territory ("Royalties").

     5.2 Royalty Term. The Royalties shall be payable on a country-by-country
basis until the sooner of (a) the introduction of an AB rated generic equivalent
to the

                                      -14-
<PAGE>
LidoPAIN(R) BP Product in such country or (b) the expiration of the last EpiCept
Patent containing a Valid Claim covering the LidoPAIN(R) BP Product in such
country (the "Royalty Term").

     5.3 Reports and Payments.

          (a) Cumulative Royalties. During the Royalty Term, the obligation to
pay Royalties under this Article 5 shall be imposed only once (i) with respect
to any sale of the same unit of the LidoPAIN(R) BP Product, and (ii) with
respect to a single unit of the LidoPAIN(R) BP Product.

          (b) Statements and Payment. During the Royalty Term Endo shall deliver
to EpiCept, within *** days after the end of each calendar quarter, a report
setting forth for such calendar quarter the following information for the
LidoPAIN(R) BP Product: (i) Net Sales of the LidoPAIN(R) BP Product on a
country-by-country basis; (ii) the basis for any adjustments to the Royalties
payable on account of sales of the LidoPAIN(R) BP Product in any country; (iii)
the Royalties due to EpiCept on account of sales of the LidoPAIN(R) BP Product;
(iv) the exchange rates used in calculating any of the foregoing; and (v) the
aggregate Net Sales of the Endo BP Product in the Territory. The total Royalties
due on account of sales of the LidoPAIN(R) BP Product during such calendar
quarter and any one-time bonus due EpiCept pursuant to Section 4.2(b)(3) above
shall be remitted at the time such report is made.

     5.4 Taxes and Withholding. Any payments made by Endo to EpiCept under this
Agreement shall be reduced by the amount required to be paid or withheld
pursuant to any applicable law, including, but not limited to, United States
federal, state or local tax law ("Withholding Taxes"). Any such Withholding
Taxes required by law to be paid or withheld shall be an expense of, and borne
solely by, EpiCept. Endo, as applicable, shall submit to EpiCept reasonable
proof of payment of the Withholding Taxes, together with an accounting of the
calculations of such taxes, within thirty (30) days after such Withholding Taxes
are remitted to the proper authority. The Parties will cooperate reasonably in
completing and filing documents required under the provisions of any applicable
tax laws or under any other applicable law in connection with the making of any
required tax payment or withholding payment, or in connection with any claim to
a refund of or credit for any such payment.

     5.5 Currency Exchange. With respect to Net Sales invoiced or expenses
incurred in U.S. dollars, the Net Sales or expense amounts and the amounts due
to EpiCept hereunder shall be expressed in U.S. dollars. With respect to Net
Sales invoiced or expenses incurred in a currency other than U.S. dollars, the
Net Sales or expense shall be expressed in the domestic currency of the entity
making the sale or incurring the expense, together with the U.S. dollar
equivalent, at the average rate of exchange listed in The Wall Street Journal on
the first and last day of the applicable calendar quarter or a comparable
newspaper if The Wall Street Journal shall cease publishing exchange rates for
the U.S. Dollar. All payments shall be made by wire transfer in U.S. dollars to
the

                                      -15-
<PAGE>
credit of such bank account as shall be designated at least five (5) Business
Days in advance by EpiCept in writing to Endo.

     5.6 Maintenance of Records; Audit.

          (a) For a period of two (2) years, Endo shall maintain, and shall
require its respective Affiliates and sublicensees to maintain, complete and
accurate books and records in connection with the sale of Licensed Products
hereunder, as necessary to allow the accurate calculation consistent with GAAP
of the Royalties due to EpiCept and any one-time bonus that may be due to
EpiCept pursuant to Section 4.2(b)(3) above, including any records required to
calculate any royalty adjustments hereunder. Once per calendar year, EpiCept
shall have the right, at its sole expense, to engage an independent accounting
firm reasonably acceptable to Endo, which shall have the right to examine in
confidence the relevant Endo records as may be reasonably necessary to determine
and/or verify the amount of Royalty payments and/or one-time bonuses due
hereunder. Such examination shall be conducted, and Endo shall make its records
available, during normal business hours, after at least fifteen (15) days prior
written notice to Endo, as applicable, and shall take place at the facility(ies)
where such records are maintained. Each such examination shall be limited to
pertinent books and records for any year ending not more than twelve (12) months
prior to the date of request; provided that EpiCept shall not be permitted to
audit the same period of time more than once. Before permitting such independent
accounting firm to have access to such books and records, Endo may require such
independent accounting firm and its personnel involved in such audit, to sign a
confidentiality agreement (in form and substance reasonably acceptable to Endo)
as to any confidential information which is to be provided to such accounting
firm or to which such accounting firm will have access, while conducting the
audit under this Section 5.5. The EpiCept independent accounting firm will
prepare and provide to each Party a written report stating whether the Royalty
and Net Sales reports submitted and the amounts paid by Endo to EpiCept are
correct or incorrect and the details concerning any discrepancies. Such
accounting firm may not reveal to EpiCept any information learned in the course
of such audit other than the amount of any such discrepancies. EpiCept agrees to
hold in strict confidence all information disclosed to it, except to the extent
necessary for EpiCept to enforce its rights under this Agreement or if
disclosure is required by law.

          (b) In the event there was an underpayment by Endo hereunder, Endo
shall promptly (but in no event later than thirty (30) days after Endo's receipt
of the independent auditor's report so correctly concluding) either make payment
to EpiCept of any shortfall or proceed to the dispute resolution mechanism set
forth in Section 5.5(c). In the event that there was an overpayment by Endo
hereunder, EpiCept shall promptly inform Endo of such fact and promptly (but in
no event later than thirty (30) days after EpiCept's receipt of the independent
auditor's report so correctly concluding) refund to Endo the excess amount or
proceed to the dispute resolution mechanism set forth in Section 5.5(c).

                                      -16-
<PAGE>
          (c) In the event that the Parties do not agree on the amount of any
overpayment or underpayment, within ten (10) business days each Party shall
select an independent public accounting firm which firms shall meet and discuss
the amount in dispute and other related matters within ten (10) business days
thereafter (each Party shall pay the costs of its own accounting firm). If such
independent public accounting firms cannot agree on a resolution mutually
agreeable to the Parties, such independent public accounting firms shall, within
ten (10) business days after such conclusion, appoint a third independent public
accounting firm which shall resolve the issue within ten (10) business days
after its selection and the Parties shall equally share the costs of such
accounting firm. The recommendation of the third independent public accounting
firm shall be final and binding upon the Parties. A judgment on such firm's
disposition may be entered in any court having jurisdiction over the Parties. In
addition, if in the final disposition of such matter, the amount of underpayment
by Endo is either (a) more than *** of the amount which should have been paid to
EpiCept pursuant to this Agreement with respect to the period in question as a
result of incorrect reporting or calculation by Endo or (b) due to Endo
incorrectly reporting or calculating the Net Sales of the Endo BP Product above
Endo Baseline Sales by more than ***, then, in either case, Endo shall also
reimburse EpiCept for its documented reasonable out-of-pocket costs and expenses
incurred in connection with resolving such matter through the retention of such
accounting firms (including, without limitation, fees of attorneys, accountants
and other professionals). Further, if in the final disposition of such matter,
the amount of any overpayment by Endo is more than *** of the amount which
should have been paid to EpiCept pursuant to this Agreement with respect to the
period in question as a result of incorrect reporting or calculation by Endo,
then EpiCept shall also reimburse Endo for its documented reasonable
out-of-pocket costs and expenses incurred in connection with resolving such
matter through the retention of such accounting firms (including, without
limitation, fees of attorneys, accountants and other professionals).

     5.7 Interest on Late Payments. Any failure by Endo to make a payment of any
undisputed amount when due shall obligate Endo to pay interest to EpiCept at a
rate equal to *** per month (or the maximum allowed by law, if less), the
interest period commencing on the due date and ending on the payment date.

                                    ARTICLE 6
                    REPRESENTATIONS, WARRANTIES AND COVENANTS

     6.1 Mutual Representations and Warranties. Each Party hereby represents,
warrants and covenants to the other Party that:

          (a) such Party is a corporation or entity duly organized, validly
existing and in good standing under the laws of its state of incorporation and
has full corporate power and authority to enter into this Agreement and to carry
out the provisions hereof;

          (b) such Party is duly authorized, by all requisite corporate action,
to execute and deliver this Agreement and the execution, delivery and
performance of this

                                      -17-
<PAGE>
Agreement by such Party is within such Party's corporate powers and does not
require any shareholder action or approval, and the Person executing this
Agreement on behalf of such Party is duly authorized to do so by all requisite
corporate action;

          (c) no consent, waiver, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any
Governmental or Regulatory Authority is required on the part of such Party in
connection with the valid execution, delivery and performance of this Agreement;

          (d) this Agreement is a legal and valid obligation binding upon such
Party and enforceable in accordance with its terms except as enforceability may
be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar
laws affecting the enforcement of creditors' rights and (ii) judicial discretion
in the availability of agreeable relief;

          (e) the execution, delivery and performance by it of this Agreement
and its compliance with the terms and provisions of this Agreement does not and
will not (a) contravene or conflict with the provisions of its charter,
operating documents or bylaws, (b) contravene or conflict with or constitute a
violation of any Applicable Law, or (c) result (with or without the giving of
notice or lapse of time or both) in the creation of any Lien or Other
Encumbrance upon any of the Licensed Products or, in the case of EpiCept, the
EpiCept Licensed Intellectual Property, or constitute a default under or give
rise to any right of termination, cancellation or acceleration of any right or
any obligation by it or to a loss of any benefit relating to the Licensed
Products or, in the case of EpiCept, the EpiCept Licensed Intellectual Property,
under any provision of any contract binding upon it or by which any of the
Licensed Products or, in the case of EpiCept, the EpiCept Licensed Intellectual
Property, are or may be bound;

          (f) it shall comply in all material respects with all laws, rules and
regulations applicable to its performance under this Agreement; and

          (g) no broker, finder or similar agent has been employed by or on
behalf of such Party, and no Person with which such Party has had any dealings
or communications of any kind is entitled to any brokerage commission, finder's
fee or any similar compensation, in connection with this Agreement or the
transactions contemplated hereby.

     6.2 Additional EpiCept Representations, Warranties and Covenants. EpiCept
additionally represents, warrants and covenants to Endo that:

          (a) EpiCept has the full right, power and authority to grant, and is
not prohibited by the terms of any agreement to which it is a party from
granting, the licenses granted to Endo under Article 2 hereof.

          (b) EpiCept has not previously granted and will not grant any rights
inconsistent with the rights and licenses granted herein.

                                      -18-
<PAGE>
          (c) EpiCept Third Party Consents. Schedule 6.2(c) sets forth each
agreement binding upon EpiCept requiring a consent with respect to the
execution, delivery and performance of this Agreement, or the performance of
EpiCept's obligations hereunder (each such consent, a "EpiCept Third Party
Consent" and together the "EpiCept Third Party Consents").

          (d) EpiCept is the sole and exclusive legal and equitable owner of the
EpiCept Intellectual Property and the LidoPAIN(R) BP Product and has good and
marketable title to the EpiCept Intellectual Property and the LidoPAIN(R) BP
Product free and clear of any Lien or Other Encumbrance.

          (e) Licensed Assets. The EpiCept Intellectual Property includes all of
the assets and properties that are owned or licensed by EpiCept with respect to
the development, marketing and sale of the LidoPAIN(R) BP Product and that are
reasonably required to develop, sell and ship the LidoPAIN(R) BP Product after
the Effective Date, No Affiliate of EpiCept owns or licenses any assets or
properties reasonably necessary for Endo to develop, produce or sell the
Licensed Products as contemplated herein. EpiCept possesses or controls all
material EpiCept Product Registration Data.

          (f) Intellectual Property.

               (i) The EpiCept Intellectual Property includes all the
intellectual property and proprietary rights Controlled by EpiCept that relate
to the development, marketing, use, distribution and sale of the LidoPAIN(R) BP
Product;

               (ii) No Action or Proceeding relating to the EpiCept Intellectual
Property has been instituted and is pending, or to the Knowledge of EpiCept,
threatened;

               (iii) There are no royalty, commission or similar obligations on
EpiCept applicable to the EpiCept Intellectual Property, or any material
licenses, sublicenses or agreements with third parties relating to or involving
the EpiCept Intellectual Property;

               (iv) EpiCept has not agreed to indemnify any Person for or
against any infringement by the EpiCept Intellectual Property or the LidoPAIN(R)
BP Product;

               (v) To the Knowledge of EpiCept, none of the EpiCept Intellectual
Property or the LidoPAIN(R) BP Product infringes upon or otherwise violates the
intellectual property rights of any Person;

               (vi) To the Knowledge of EpiCept, the EpiCept Intellectual
Property is valid and enforceable and has been properly registered or filed, as
the case may be, and has been properly maintained under all Applicable Laws.

                                      -19-
<PAGE>
               (vii) EpiCept owns all right, title and interest in and to all of
the EpiCept Intellectual Property and owns such EpiCept Intellectual Property
free and clear of all Liens or Other Encumbrances.

               (viii) EpiCept has not received any written notice from any Third
Party, nor does EpiCept have Knowledge that any Third Party has infringed or
misappropriated or is infringing or misappropriating any of the EpiCept
Intellectual Property.

          (g) Regulatory Status.

               (i) EpiCept is the lawful holder of the IND and all necessary
regulatory documentation relating to the LidoPAIN(R) BP Product. The regulatory
status of the LidoPAIN(R) BP Product is set forth in Schedule 6.2(g)(i).

               (ii) The IND is in full force and effect and, to the Knowledge of
EpiCept, the IND has been duly and validly issued. There is no Action or
Proceeding by any Governmental or Regulatory Authority pending or, to the
Knowledge of EpiCept, threatened seeking the revocation or suspension of any of
the IND.

          (h) EpiCept has no Knowledge of any facts which furnish any reasonable
basis for any notice of adverse findings, warning or other regulatory letters or
sanctions, Section 305 notices, or other similar communication. EpiCept has no
Knowledge of any misstatements or material omissions relating to the LidoPAIN(R)
BP Product in any regulatory submission or other document required to be
maintained by Applicable Law and the accuracy of its regulatory submissions has
not been contested by any Governmental or Regulatory Authority.

          (i) Litigation. There are no Actions or Proceedings by or before any
Governmental or Regulatory Authority currently pending, and EpiCept has not
received any written notice from any Third Party of any Action or Proceeding,
nor does EpiCept have Knowledge of any facts that would be reasonably likely to
result in an Action or Proceeding, in any event, against EpiCept relating to,
affecting or arising in connection with (a) the LidoPAIN(R) BP Product; (b) the
EpiCept Licensed Intellectual Property, (c) this Agreement; or (d) the
transactions contemplated by this Agreement. EpiCept is not subject to any Order
relating to the LidoPAIN(R) BP Product or the EpiCept Licensed Intellectual
Property.

     6.3 Additional Endo Representations, Warranties and Covenants. Endo
additionally represents, warrants and covenants to EpiCept that, as of the
Effective Date, Endo has the financial capacity to perform its obligations under
this Agreement.

     6.4 Disclaimer of Warranties. EXCEPT AS OTHERWISE SPECIFICALLY PROVIDED IN
THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS,
IMPLIED, STATUTORY OR OTHERWISE, CONCERNING THE SUCCESS OR POTENTIAL SUCCESS OF
THE

                                      -20-
<PAGE>
DEVELOPMENT, COMMERCIALIZATION, MARKETING OR SALE OF ANY LICENSED PRODUCT.
EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL
WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE
IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

                                    ARTICLE 7
              CONFIDENTIALITY, PUBLICATION AND PUBLIC ANNOUNCEMENTS

     7.1 Confidentiality. Except to the extent expressly authorized by this
Agreement or otherwise agreed in writing, Endo and EpiCept agree that, until the
fifth (5th) anniversary of the expiration or termination this Agreement, each of
Endo and EpiCept, upon receiving or learning of any Confidential Information of
the other Party, shall keep such Confidential Information confidential and
otherwise shall not disclose or use such Confidential Information for any
purpose other than as provided for in this Agreement. The Receiving Party may
disclose Confidential Information to its employees, representatives or
Affiliates who need to know such information for any purpose contemplated by
this Agreement (and then only to the extent that such Persons need to know such
information and are under an obligation at least as stringent as this Article 7
to maintain the confidentiality of the Confidential Information). The Receiving
Party may disclose Confidential Information to its consultants so long as the
Disclosing Party approves of such disclosure in writing prior thereto and such
consultant is under an obligation at least as stringent as this Article 7 to
maintain the confidentiality of the Confidential Information.

     7.2 Authorized Disclosure. Notwithstanding the foregoing, each of Endo and
EpiCept may disclose Confidential Information of the other Party to a Third
Party to the extent such disclosure is reasonably necessary to exercise the
rights granted to or retained by it under this Agreement in filing or
prosecuting patent applications, prosecuting or defending litigation, complying
with applicable governmental regulations, submitting information to tax or other
governmental authorities (including Regulatory Authorities), or conducting
clinical trials hereunder with respect to Licensed Products, provided that if a
Party is required by law to make any such disclosure of the Disclosing Party's
Confidential Information, to the extent it may legally do so, it will give
reasonable advance notice to the Disclosing Party of such disclosure and, save
to the extent inappropriate in the case of patent applications or otherwise,
will use its reasonable efforts to secure confidential treatment of such
Confidential Information prior to its disclosure (whether through protective
orders or otherwise). If the Disclosing Party has not filed a patent application
with respect to such Confidential Information, it may require the Receiving
Party to delay the proposed disclosure (to the extent the disclosing party may
legally do so), for up to ninety (90) days, to allow for the filing of such an
application.

     7.3 Return of Confidential Information. Upon termination of this Agreement
except upon termination by expiration of the licenses granted hereunder, the
Receiving

                                      -21-
<PAGE>
Party shall promptly return or, at the option of the Receiving Party, destroy,
all of the Disclosing Party's Confidential Information, including all
reproductions and copies thereof in any medium, except that the Receiving Party
may retain one copy for its legal files; provided that any such destruction
shall be confirmed in writing by the Receiving Party to the Disclosing Party.

     7.4 Unauthorized Use. If either Party becomes aware or has Knowledge of any
unauthorized use or disclosure of the other Party's Confidential Information, it
shall promptly notify the disclosing Party of such unauthorized use or
disclosure.

     7.5 Public Announcements. Except as set forth in the press release agreed
to by the Parties pursuant to this Section 7.5 and for filing a copy of this
Agreement by Endo and/or EpiCept (in the event that EpiCept becomes, or files to
become, a public company), with the Securities and Exchange Commission (provided
that in any such filing, this Agreement shall be redacted as reasonably
determined by the filing Party), to the extent Endo and/or EpiCept determines to
make such a filing and for disclosure by EpiCept to its present and prospective
investors, counselors and advisors and investment banks and other Persons in
connection with its financing activities, neither Party shall make any public
announcement regarding this Agreement, any EpiCept Intellectual Property or any
Licensed Products, unless required by law, and then only after providing the
other Party at least two (2) Business Days to review, comment on and approve
such public announcement; provided, however, the Parties agree that a period of
less than two (2) Business Days for review, comment and approval is permissible
if such lesser period of time is necessitated in order to comply with law or by
an emergency situation due to unexpected circumstances. The Parties agree to
issue a press release announcing the execution of this Agreement. In addition,
following the initial agreed upon press release announcing this Agreement, each
Party shall be free to disclose, without the other Parties' prior written
consent, the existence of this Agreement, the identity of the other Party and
those terms of the Agreement which have already been publicly disclosed in
accordance herewith. This Section 7.5 supersedes and replaces in its entirety
any prior confidentiality agreements between EpiCept or its Affiliates and Endo
or its Affiliates to the extent related to the transactions contemplated by this
Agreement or the LidoPAIN(R) BP Product.

                                    ARTICLE 8
                                 INDEMNIFICATION

     8.1 Endo. Endo shall defend EpiCept and its Affiliates at Endo's cost and
expense, and will indemnify and hold EpiCept and its Affiliates and their
respective directors, officers, employees and agents (collectively, the "EpiCept
Indemnified Parties") harmless from and against any and all losses, costs,
damages, fees or expenses (including reasonable attorneys' fees and expenses)
("Losses") incurred by any EpiCept Indemnified Party to the extent arising out
of or resulting from (i) any material breach by Endo of any of its
representations, warranties or obligations pursuant to this Agreement, (ii) any
gross negligence or willful misconduct of Endo or its Affiliates or
sublicensees, as applicable, in the exercise of any of their rights and/or the
performance of any of their

                                      -22-
<PAGE>
obligations under this Agreement or any sublicense agreement, as applicable,
(iii) any liability or other claims arising from the manufacture, handling,
packaging, storage, sale or other disposition of the Endo BP Product by Endo or
any of its Affiliates or sublicensees, or (iv) any liability or other claims
arising from the marketing of the LidoPAIN(R) BP Product by Endo or any of its
Affiliates or sublicensees.

     8.2 EpiCept. EpiCept agrees to defend Endo and its Affiliates at EpiCept's
cost and expense, and will indemnify and hold Endo and its Affiliates and their
respective directors, officers, employees and agents (collectively, the "Endo
Indemnified Parties") harmless from and against any and all Losses incurred by
any Endo Indemnified Party to the extent arising out of or resulting from (i)
any material breach by EpiCept of any of its representations, warranties or
obligations pursuant to this Agreement, (ii) any gross negligence or willful
misconduct of EpiCept in the exercise of any of its rights or the performance of
any of its obligations under this Agreement, or (iii) any product liability,
clinical trial liability or other claims arising from the development,
manufacture, handling, or packaging of the LidoPAIN(R) BP Product.

     8.3 Indemnification Procedures.

          (a) Any Party seeking indemnification pursuant to this Article 8 (the
"Indemnitee") shall give the other party or parties from whom indemnification is
sought (the "Indemnitor") prompt written notice (an "Indemnification Claim
Notice") of any Loss or discovery of fact upon which such Indemnitee is seeking
indemnification under this Article 8. Failure to give any such Indemnification
Claim Notice shall not constitute a waiver of any right to indemnification or
reduce in any way the indemnification available hereunder, except to the extent
such failure to notify directly increases the amount to be indemnified
hereunder. Each Indemnification Claim Notice must contain a description of the
claim and the nature and amount of such Losses (to the extent that the nature
and amount of such Loss is known at such time). The Indemnitee shall furnish
promptly to the Indemnitor copies of all papers and official documents received
in respect of any such Loss. All indemnification claims hereunder, whether in
respect of Endo, EpiCept, their respective Affiliates or their respective
directors, officers, employees and agents, shall be made solely by Endo or
EpiCept, as applicable, as the Party to this Agreement.

          (b) In the case of Losses arising from claims of any Third Party that
are subject to indemnification provided in this Article 8 (a "Third Party
Claim"), as to which the Indemnitor may be obligated to provide indemnification
pursuant to this Agreement, the Indemnitee will notify the Indemnitor in writing
of the Third Party Claim (and specifying in reasonable detail the factual basis
for the Third Party Claim and to the extent known, the amount of the Third Party
Claim) reasonably promptly after becoming aware of such Third Party Claim;
provided, however, that failure to give such notification will not affect the
indemnification provided hereunder except to the extent the Indemnitor shall
have been actually prejudiced as a result of such failure.

                                      -23-
<PAGE>
          (c) If a Third Party Claim is made against an Indemnitee and the
Indemnitor acknowledges in writing its obligation to indemnify the Indemnitee
therefor, the Indemnitor will be entitled, within one hundred twenty (120) days
after receipt of written notice from the Indemnitee of the commencement or
assertion of any such Third Patty Claim, to assume the defense thereof (at the
expense of the Indemnitor) with counsel selected by the Indemnitor and
reasonably satisfactory to the Indemnitee, for so long as the Indemnitor is
conducting a good faith and diligent defense. Should the Indemnitor so elect to
assume the defense of a Third Party Claim, the Indemnitor will not be liable to
the Indemnitee for any legal or other expenses subsequently incurred by the
Indemnitee in connection with the defense thereof provided that if under
applicable standards of professional conduct a conflict of interest exists
between the Indemnitor and the Indemnitee in respect of such claim, such
Indemnitee shall have the right to employ separate counsel to represent such
Indemnitee with respect to the matters as to which a conflict of interest exists
and in that event the reasonable fees and expenses of such separate counsel
shall be paid by such Indemnitor; provided, further, that the Indemnitor shall
only be responsible for the reasonable fees and expenses of one separate counsel
for such Indemnitee; provided still further that the Indemnitor and its counsel
shall cooperate with the Indemnitee and its counsel, as may be reasonably
requested. If the Indemnitor assumes the defense of any Third Party Claim, and
no such conflict of interest exists, the Indemnitee shall have the right to
participate in the defense thereof and to employ counsel, at its own expense,
separate from the counsel employed by the Indemnitor. If the Indemnitor assumes
the defense of any Third Party Claim, the Indemnitor will promptly supply to the
Indemnitee copies of all correspondence and documents relating to or in
connection with such Third Party Claim and keep the Indemnitee informed of
developments relating to or in connection with such Third Party Claim, as may be
reasonably requested by the Indemnitee (including, without limitation, providing
to the Indemnitee on reasonable request updates and summaries as to the status
thereof). If the Indemnitor chooses to defend a Third Party Claim, all
Indemnitees shall reasonably cooperate with the Indemnitor in the defense
thereof (such cooperation to be at the expense, including reasonable legal fees
and expenses, of the Indemnitor). If the Indemnitor does not elect to assume
control of the defense of any Third Party Claim within the one hundred twenty
(120) day period set forth above, or if such good faith and diligent defense is
not being or ceases to be conducted by the Indemnitor, the Indemnitee shall have
the right, at the expense of the Indemnitor, after three (3) Business Days
notice to the indemnitor of its intent to do so, to undertake the defense of the
Third Party Claim for the account of the Indemnitor (with counsel selected by
the Indemnitee), and to compromise or settle such Third Party Claim, exercising
reasonable business judgment.

          (d) If the Indemnitor acknowledges in writing its obligation to
indemnify the Indemnitee for a Third Party Claim, the Indemnitee will agree to
any settlement, compromise or discharge of such Third Party Claim that the
Indemnitor may recommend that by its terms obligates the Indemnitor to pay the
full amount of Losses (whether through settlement or otherwise) in connection
with such Third Party Claim and unconditionally and irrevocably releases the
Indemnitee completely from all liability in connection with such Third Party
Claim; provided, however, that, without the

                                      -24-
<PAGE>
Indemnitee's prior written consent, the Indemnitor shall not consent to any
settlement, compromise or discharge (including the consent to entry of any
judgment), and the Indemnitee may refuse in good faith to agree to any such
settlement, compromise or discharge, that provides for injunctive or other
nonmonetary relief affecting the Indemnitee. If the Indemnitor acknowledges in
writing its obligation to indemnify the Indemnitee for a Third Party Claim, the
Indemnitee shall not (unless required by law) admit any liability with respect
to, or settle, compromise or discharge, such Third Party Claim without the
Indemnitor's prior written consent (which consent shall not be unreasonably
withheld).

     8.4 Insurance Proceeds. Any indemnification hereunder shall be made net of
any insurance proceeds recovered by the Indemnitee (it being understood that an
Indemnitee may simultaneously pursue an insurance claim and a claim for
indemnification hereunder); provided, however, that if, following the payment to
the Indemnitee of any amount under this Article 8, such Indemnitee recovers any
insurance proceeds in respect of the claim for which such indemnification
payment was made, the Indemnitee shall promptly pay an amount equal to the
amount of such proceeds (but not exceeding the amount of such indemnification
payment) to the Indemnitor.

     8.5 Insurance. Each Party agrees to obtain and maintain commercial general
liability insurance, including clinical trials and products liability insurance,
with reputable and financially secure insurance carriers, or to be self-insured,
in either case, in such amounts and subject to such deductibles as are
reasonable and customary in the pharmaceutical industry for companies of
comparable size and activities. Each Party shall maintain such insurance for so
long as Licensed Products in the Territory continue to be manufactured or sold
and thereafter for so long as is necessary to cover any and all Third Party
Claims which may arise from the development, manufacture or sale of a Licensed
Product in the Territory. Upon reasonable request by a Party, the other Party
shall produce evidence that such insurance policies are valid, kept up to date
and in full force and effect.

                                    ARTICLE 9
                              TERM AND TERMINATION

     9.1 Term.

          (a) Except as set forth in Section 11.13, unless earlier terminated by
mutual agreement of the Parties in writing or pursuant to the provisions of this
Article 9, this Agreement will continue in full force and effect until the later
of (i) the conclusion of the Royalty Term on a country-by-country basis and (ii)
the expiration of the last EpiCept Licensed Patent containing a Valid Claim
covering the Endo BP Product on a country-by-country basis (the "Term").

          (b) On a country-by-country basis, at the conclusion of the Royalty
Term, the licenses granted hereunder with respect to the LidoPAIN(R) BP Product
and the Endo BP Product, respectively, shall become fully paid up, royalty-free,
perpetual and

                                      -25-
<PAGE>
irrevocable and the exclusivity restrictions pursuant to Section 2.3 with
respect to each such country shall no longer be applicable.

     9.2 Material Breach. Upon a material breach of this Agreement by Endo on
the one hand, or EpiCept on the other hand (in such capacity, the "Breaching
Party"), the other Party (in such capacity, the "Non-Breaching Party") may
provide written notice (a "Breach Notice") to the Breaching Party specifying the
material breach. If the Breaching Party fails to cure such material breach
during the forty-five (45) day period (or, if applicable, such longer period,
but not to exceed ninety (90) days, as would be reasonably necessary for a
diligent party to cure such material breach, provided the Breaching Party has
commenced and continues its diligent efforts to cure during the initial
forty-five (45) day period following the date on which the Breach Notice is
provided), then the Non-Breaching Party may terminate this Agreement on a
Licensed Product-by-Licensed Product and country-by-country basis with respect
to the Licensed Product and country to which the breach relates. If Endo is the
Breaching Party and the material breach relates to the LidoPAIN(R) BP Product in
a particular country within the Territory and EpiCept has elected to terminate
this Agreement with respect to the LidoPAIN(R) BP Product in such country, the
exclusivity restrictions pursuant to Section 2.3 with respect to such country
shall no longer be applicable with respect to the LidoPAIN(R) BP Product.
Notwithstanding the foregoing, the cure period for any failure by Endo to make
Milestone Payments or Royalty payments due hereunder shall be forty-five (45)
days; provided further, however, that the failure by Endo to make any such
payment shall not be considered a breach to the extent that such payment is the
subject of a good faith dispute by Endo. For the purposes of this Section 9.2,
material breach shall mean a breach which materially adversely affects the
rights under this Agreement of the other Party with respect to the applicable
Licensed Product in the applicable country in the Territory.

     9.3 Bankruptcy. Either Party may, subject to the provisions set forth
herein, terminate this Agreement by giving the other Party sixty (60) days'
written termination notice if, at any time, the other Party shall: (a) file in
any court pursuant to any statute a petition for bankruptcy or insolvency, or
for reorganization in bankruptcy, or for an arrangement or for the appointment
of a receiver, trustee or administrator of such Party or of its assets; (b) be
served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition shall not be dismissed within sixty (60) days
after the filing thereof; (c) propose or be a party to any dissolution; or (d)
make an assignment for the benefit of its creditors. Should EpiCept become a
party to a bankruptcy proceeding and such proceeding is not dismissed within
sixty (60) days then, to the extent permitted by law, this Agreement and the
licenses granted by EpiCept hereunder shall be adopted by any bankruptcy trustee
or relevant Third Party charged with the disposition of same, and shall not be
rejected by same, it being the Parties' intent that, in such event, Endo and its
Affiliates and sublicensees shall be entitled to retain the rights granted to
them hereunder by EpiCept.

     9.4 Continuing Rights of Sublicensees. Upon any termination of this
Agreement, each sublicense previously granted by Endo, or any of its Affiliates,
to any

                                      -26-
<PAGE>
Person that is not an Affiliate of Endo (each, an "Independent Sublicensee")
shall, at EpiCept's option, remain in effect and shall become a direct license
or sublicense, as the case may be, of such rights by EpiCept to such Independent
Sublicensee, subject to the Independent Sublicensee agreeing in writing to
assume Endo's terms, conditions and obligations to EpiCept under this Agreement
as they pertain to the sublicensed rights.

     9.5 Effect of Expiration or Termination. Expiration or termination of this
Agreement pursuant to this Article 9 shall not (i) relieve a Party hereto of any
obligation accruing to such Party prior to such termination, or (ii) result in
the waiver of any right or remedy by a Party hereto accruing to such Party prior
to such termination.

     9.6 Limitation of Liabilities. NOTWITHSTANDING THE FOREGOING, EXCEPT AS MAY
BE THE CASE UNDER ARTICLE 8 ABOVE WITH RESPECT TO INDEMNIFICATION FOR THIRD
PARTY CLAIMS, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR PUNITIVE,
EXEMPLARY, SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING
WITHOUT LIMITATION LOST PROFITS, BUSINESS OR GOODWILL) ATTRIBUTABLE TO ANY
BREACH OR DEFAULT BY SUCH PARTY UNDER THIS AGREEMENT. THIS LIMITATION SHALL
SURVIVE ANY FAILURE OF THE ESSENTIAL PURPOSE OF A LIMITED OR EXCLUSIVE REMEDY
SET FORTH HEREIN.

                                   ARTICLE 10
                              INTELLECTUAL PROPERTY

     10.1 Ownership of Technology and Patent Rights.

          (a) EpiCept shall own any Technology and EpiCept Improvements claiming
such Technology, invented, developed or discovered solely by EpiCept or its
Affiliate's employees or agents.

          (b) Endo shall own any Technology, and any patent rights claiming such
Technology, invented, developed or discovered solely by Endo's or its
Affiliate's employees or agents.

     10.2 Prosecution of EpiCept Licensed Patents. EpiCept shall have the
obligation to diligently Prosecute the patent rights within the EpiCept Licensed
Patents and EpiCept Improvements in the Territory, through patent counsel
selected by EpiCept. EpiCept and Endo shall consult and cooperate with each
other regarding the Prosecution of the EpiCept Licensed Patents. Endo shall
reimburse EpiCept for *** of the Prosecution costs incurred by EpiCept after the
Effective Date within thirty (30) days of Endo's receipt of an invoice therefor.

     10.3 Right to Consult. During the Term of this Agreement, EpiCept shall
copy Endo, or have Endo copied, on all substantive documents relating to EpiCept
Licensed Patents and EpiCept Improvements received from or to be filed in any
patent office in the

                                      -27-
<PAGE>
Territory, within fifteen (15) days of receipt from the patent office and at
least fifteen (15) days prior to filing with the patent office, respectively,
including without limitation copies of each patent application, official action,
response to official action, declaration, information disclosure statement,
request for terminal disclaimer, request for patent term extension, and request
for reexamination. Endo shall have the right to comment on the Prosecution of
the EpiCept Licensed Patents and EpiCept Improvements and provide such comments
to EpiCept's patent counsel, and EpiCept shall require its patent counsel to
consider in good faith such comments from Endo, and, to the extent not
inconsistent with EpiCept's rights and/or commercial interests, EpiCept shall
require its patent counsel to incorporate all such comments. In the event that
Endo's comments are inconsistent with EpiCept's rights and/or commercial
interests, EpiCept and Endo agree to negotiate in good faith a Prosecution
strategy with respect to the relevant EpiCept Licensed Patents and/or EpiCept
Improvements that would adequately cover Endo's interests, without adversely
affecting EpiCept's rights and/or commercial interests. If Endo fails to provide
its comments with respect to the Prosecution of a patent application and/or
Patent within the EpiCept Licensed Patents and/or EpiCept Improvements at least
five (5) days prior to the deadline for filing or otherwise responding to the
relevant paper in the relevant patent office, EpiCept shall be free to act
without consideration of Endo's comments.

     10.4 Abandonment of Prosecution by EpiCept. EpiCept shall notify Endo in
the event it is unable for any reason to meet its obligations under Section
10.2. Such notification shall be given within a reasonable period (i.e., with
sufficient time for Endo to take whatever action may be necessary or desired)
prior to the date on which such patent application(s) or patent(s) will lapse or
go abandoned. Endo shall then have the option, exercisable upon written
notification to EpiCept, to assume full responsibility, at its discretion and
its sole cost and expense, for Prosecution of the affected patent application(s)
or maintenance of any of the affected Patent(s) in such country or countries in
the Territory; provided, however, Endo may offset any such costs and expenses
against any Milestone Payments or Royalties due to EpiCept.

     10.5 Patent Term Extensions. Endo shall have the right to request that
EpiCept file all applications and take actions necessary to obtain patent
extension pursuant to 35 U.S.C. Section 156 or like foreign statutes for the
EpiCept Licensed Patents in the Territory, which extensions shall be owned by
EpiCept. If EpiCept declines to pursue such patent extensions, then Endo shall
have the right (at Endo's cost and expense) on behalf of EpiCept to file all
such applications and take all such actions necessary to obtain such patent
extensions. EpiCept agrees to sign such further document and take such further
actions (all at Endo's expense) as may be requested by Endo in this regard.

     10.6 Patent Marking. Endo and its Affiliates and its sublicensees shall
mark all Licensed Products made or sold under this Agreement with a notice in
accordance with 35 U.S.C. Section 287 and similar marking provisions in foreign
countries. The Parties agree that listing of the patent numbers in the package
inserts or foreign equivalent shall be considered sufficient marking of Licensed
Products as required by this Section 10.6.

                                      -28-
<PAGE>
     10.7 Third Party Infringements.

          (a) Suits for Infringement of the EpiCept Licensed Patents and EpiCept
Improvements. If EpiCept or Endo becomes aware of infringement of any Patent
included in the EpiCept Licensed Patents or EpiCept Improvements by a Third
Party in the Territory, such Party shall promptly notify the other Party in
writing to that effect and provide a summary of the relevant facts and
circumstances known to such Party relating to such infringement ("Infringement
Notice"). EpiCept shall have the right, at its sole discretion, on its own
behalf, to institute, prosecute and control any action or proceeding to restrain
infringement of any EpiCept Licensed Patents or EpiCept Improvements licensed to
Endo hereunder. Endo agrees to be joined as a Party plaintiff if necessary to
prosecute the action or proceeding and shall provide all reasonable cooperation,
including any necessary use of its name, required to prosecute such litigation.
EpiCept shall have sole control of any such suit and all negotiations for its
settlement or compromise, provided that, EpiCept shall not settle or compromise
any such suit or enter into any consent order for the settlement or compromise
thereof without the prior written consent of Endo, which consent shall not be
unreasonably withheld, conditioned or delayed.

          (b) Step-in Right for Endo. If, prior to the expiration of three (3)
months from said Infringement Notice, EpiCept has not obtained a discontinuance
of an alleged infringement by a Third Party or brought an infringement action or
proceeding or otherwise taken appropriate action to abate such infringement, or,
in the event that a Third Party files a paragraph IV certification relating to
any Patent pursuant to 21 U.S.C. Section 355(j)(2)(A)(vii)(IV) of the
Hatch/Waxman Act (or any successor statute), if EpiCept does not institute an
infringement proceeding against such Third Party within 20 days of receipt of
notice of such paragraph IV certification, or if EpiCept shall notify Endo at
any time prior thereto of its intention not to bring suit against an alleged
infringer or EpiCept at any time ceases to actively prosecute any such ongoing
infringement, and such infringement is relevant to a Licensed Product in the
Territory, then, and in those events only, Endo shall have the right, but not be
obligated, to institute, prosecute and control any action or proceeding to
restrain such infringement. EpiCept agrees to be joined as a Party plaintiff if
necessary to prosecute the action or proceeding and shall provide all reasonable
cooperation, including any necessary use of its name, required to prosecute such
litigation. Endo shall have sole control of any such suit and all negotiations
for its settlement or compromise, provided that Endo shall not settle or
compromise any such suit or enter into any consent order for the settlement or
compromise thereof without the prior written consent of EpiCept, which consent
shall not be unreasonably withheld, conditioned or delayed.

          (c) Costs and Recoveries from Infringement Action. Each Party shall
assume and pay all of its own out-of-pocket costs incurred in connection with
any litigation or proceedings described in this Section 10.7 including, without
limitation, the fees and expenses of that Party's counsel. Any recovery obtained
by any Party as a result of any proceeding described in this Section 10.7, by
settlement or otherwise, shall be applied in the following order of priority:
(i) first, to reimburse each Party for all

                                      -29-
<PAGE>
litigation costs in connection with such proceeding paid by that Party and not
otherwise recovered (on a pro rata basis based on each Party's respective
litigation costs, to the extent the recovery was less than all such litigation
costs); and (ii) second, the remainder of the recovery shall be shared equally.

          (d) Declaratory Actions & Counterclaims Against Endo or EpiCept. In
the event that an action alleging invalidity or non-infringement of any of the
EpiCept Licensed Patents or EpiCept Improvements shall be brought against
EpiCept or Endo, EpiCept, at its sole discretion, shall have the right, within
thirty (30) days after the commencement of such action, to take or regain
control of the action at its own expense. If EpiCept shall determine not to
exercise this right, Endo may take over or remain as lead counsel for the action
at Endo's sole discretion. Any recovery obtained from such litigation,
proceeding or settlement shall be shared in accordance with Section 10.7(c). Any
amounts owed in such litigation, proceeding or settlement shall be paid by
EpiCept.

     10.8 Infringement of Third Party Rights.

          (a) Infringement Claims. With respect to any and all claims instituted
by Third Parties for patent infringement involving the manufacture, use, offer
for sale or sale of a Licensed Product covered by the EpiCept Licensed Patents
or EpiCept Improvements in the Territory during the Term, except for any such
claims for which EpiCept is obligated to indemnify Endo under Section 8.2, Endo
shall promptly notify EpiCept of such claim, and Endo shall have the right, at
its sole discretion, to defend and control any action or proceeding with respect
to such claim. EpiCept agrees to be joined as a party if necessary to defend the
action or proceeding and shall provide all reasonable cooperation, including any
necessary use of its name, required to defend such litigation. Endo shall have
sole control of any such suit and all negotiations for its settlement or
compromise, provided that, Endo shall not settle or compromise any such suit or
enter into any consent order for the settlement or compromise thereof without
the prior written consent of EpiCept, which consent shall not be unreasonably
withheld, conditioned or delayed.

          (b) Step-in Right for EpiCept. If, prior to the expiration of three
(3) months from said claim being brought, or such sooner period as may be
necessary to appropriately respond to said claim, Endo has not elected to defend
such action or proceeding, or, in the event that a Third Party files a paragraph
IV certification relating to any Patent pursuant to 21 U.S.C. Section
355(j)(2)(A)(vii)(lV) of the Hatch/Waxman Act (or any successor statute), if
EpiCept does not institute an infringement proceeding against such Third Party
within 20 days of receipt of notice of such paragraph IV certification, or if
Endo shall notify EpiCept at any time prior thereto of its intention not to
defend such action or proceeding, then, and in those events only, EpiCept shall
have the right, but not be obligated, to defend and control any action or
proceeding. Endo agrees to be joined as a party if necessary to defend the
action or proceeding and shall provide all reasonable cooperation, including any
necessary use of its name, required to defend such litigation. EpiCept shall
have sole control of any such suit and all negotiations for its settlement or
compromise, provided that EpiCept shall not settle or

                                      -30-
<PAGE>
compromise any such suit or enter into any consent order for the settlement or
compromise thereof without the prior written consent of Endo, which consent
shall not be unreasonably withheld, conditioned or delayed.

                                   ARTICLE 11
                                  MISCELLANEOUS

     11.1 Assignment. This Agreement may not be assigned or otherwise
transferred (in whole or in part, whether voluntarily, by operation of law or
otherwise) by either Party without the prior written consent of the other Party
(which consent shall not be unreasonably withheld); provided, however, that such
consent shall not be required if (i) the assignment is to an Affiliate, or (ii)
the assignment is in connection with the transfer or sale of all or
substantially all of the transferor's business (whether by asset sale, merger,
consolidation, or similar transaction). This Agreement shall be binding upon the
permitted successors and assigns of the Parties.

     11.2 Further Actions. Each Party agrees to execute, acknowledge and deliver
such further instruments, and to do all such other acts, as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement.

     11.3 Force Majeure. Neither Party shall be liable to the other Party for
loss or damages, or shall have any right to terminate this Agreement for any
default or delay directly attributable to any Force Majeure, provided that the
Party affected gives prompt notice of any such cause to the other Party. The
Party giving such notice shall thereupon be excused from such of its obligations
hereunder for so long as it is thereby disabled from performing such
obligations; provided, however, that such affected Party promptly commences and
continues to use its Commercially Reasonable Efforts to cure such disablement as
soon as practicable.

     11.4 Notices. Notices to EpiCept shall be addressed to:

          EpiCept Corporation
          270 Sylvan Avenue
          Englewood Cliffs, New Jersey 07632
          Attention: Chief Executive Officer
          Facsimile No.: (201) 837-0200

          with a copy to:

          Pennie & Edmonds LLP
          1155 Avenue of the Americas
          New York, New York 10036
          Attention: Ann Gisolfi
          Facsimile No: (212) 869-9741

                                      -31-
<PAGE>
          Notices to Endo shall be addressed to:

          Endo Pharmaceuticals Inc.
          100 Painters Drive
          Chadds Ford, Pennsylvania 19317
          Attention: Chief Executive Officer
          Facsimile No.: (610) 558-9682

          with a copy to:

          Endo Pharmaceuticals Inc.
          100 Painters Drive
          Chadds Ford, Pennsylvania 19317
          Attention: General Counsel
          Facsimile No: (610) 558-9684

Either Party may change the address to which notices shall be sent by giving
notice to the other Party in the manner herein provided. Any notice required or
provided for by the terms of this Agreement shall be in writing and shall be (i)
sent by registered or certified mail, return receipt requested, postage prepaid,
(ii) sent via a reputable overnight courier service, or (iii) sent by facsimile
transmission, in each case properly addressed in accordance with the paragraphs
above. The effective date of any notice shall be as of the date received, in the
case of personal delivery, (b) on the next business day following transmission
thereof by facsimile or deposit thereof with a nationally recognized overnight
courier service, or (c) on the fifth business day following the mailing thereof
by registered or certified mail.

     11.5 Amendment. No amendment, modification or supplement of any provision
of this Agreement shall be valid or effective unless made in writing and signed
by a duly authorized officer of each Party.

     11.6 Waiver. No provision of this Agreement shall be waived by any act,
omission or Knowledge of a Party or its agents or employees except by an
instrument in writing expressly waiving such provision and signed by a duly
authorized officer of the waiving Party.

     11.7 Counterparts; Facsimile Signatures. This Agreement may be executed in
two (2) counterparts and such counterparts taken together shall constitute one
(1) and the same agreement. This Agreement may be executed by facsimile
signatures, which signatures shall have the same force and effect as original
signatures.

     11.8 Descriptive Headings. The descriptive headings of this Agreement are
for convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement.

                                      -32-
<PAGE>
     11.9 Governing Law. This Agreement shall be governed and construed in
accordance with the laws of the State of New York, without giving effect to any
choice of law provisions thereof. Each Party hereby submits itself for the
purpose of this Agreement and any controversy arising hereunder to the exclusive
jurisdiction of the state and federal courts located in the State of New York,
and any courts of appeal therefrom, and waives any objection on the grounds of
lack of jurisdiction (including, without limitation, venue) to the exercise of
such jurisdiction over it by any such courts. Prior to bringing a legal action
against the other Party, such dispute shall be separately negotiated by the
Parties hereto in good faith and all reasonable efforts undertaken to settle
amicably such matters before resorting to further legal recourse, as follows:
upon the occurrence of a dispute between the Parties, including, without
limitation, any breach of this Agreement or any obligation relating thereto, or
any dispute with respect to whether a product is a Licensed Product, the matter
shall be referred first to the officers of EpiCept and Endo having
responsibility for the subject matter of the dispute, or their designees. The
officers, or their designees, as the case may be, shall negotiate in good faith
to resolve such dispute in a mutually satisfactory manner for up to thirty (30)
days. If such efforts do not result in mutually satisfactory resolution of the
dispute, the matter shall be referred to the chief executive officers of EpiCept
and Endo, or their designees. The chief executive officers, or their designees,
as the case may be, shall negotiate in good faith to resolve such dispute in a
mutually satisfactory manner for up to thirty additional (30) days, or such
longer period of time to which the chief executive officers may agree.

     11.10 Nature of Licenses. All rights and licenses granted pursuant to this
Agreement are, and shall otherwise be deemed to be, for purposes of 11 U.S.C.
365(n) of the Bankruptcy Laws, licenses of rights to "intellectual property" as
defined under 11 U.S.C. 101(35A) of the Bankruptcy Laws. The Parties agree that
Endo, as a licensee of such rights under this Agreement, shall retain and may
fully exercise all of its rights, including any right to enforce any exclusivity
provision of this Agreement, remedies, and elections under the Bankruptcy Laws.
To the fullest extent permitted by law, the Parties further agree that, in the
event of the commencement of a bankruptcy proceeding by or against EpiCept under
the Bankruptcy Laws, Endo shall be entitled to all applicable rights under 11
U.S.C. 365(n) of the Bankruptcy Laws, including copies and access to, as
appropriate, any such intellectual property and all embodiments of such
intellectual property upon written request therefor by Endo, and such, if not
already in its possession, shall be promptly delivered to Endo.

     11.11 Severability. If any provision hereof should be held invalid, illegal
or unenforceable in any respect in any jurisdiction, the Parties hereto shall
substitute, by mutual consent, valid provisions for such invalid, illegal or
unenforceable provisions which valid provisions in their economic effect are
sufficiently similar to the invalid, illegal or unenforceable provisions that it
can be reasonably assumed that the Parties would have entered into this
Agreement with such valid provisions. In case such valid provisions cannot be
agreed upon, the invalid, illegal or unenforceable provisions of this Agreement
shall not affect the validity of this Agreement as a whole, unless the invalid,
illegal or unenforceable provisions are of such essential importance to this
Agreement

                                      -33-
<PAGE>
that it is to be reasonably assumed that the Parties would not have entered into
this Agreement without the invalid, illegal or unenforceable provisions.

     11.12 Entire Agreement of the Parties. This Agreement, together with the
exhibits and Schedules hereto, constitute and contain the complete, final and
exclusive understanding and agreement of the Parties and cancels and supersedes
any and all prior negotiations, correspondence, understandings and agreements
whether oral or written, between the Parties respecting the subject matter
hereof and thereof.

     11.13 Independent Contractors. The relationship between the Parties created
by this Agreement is one of independent contractors and neither Party shall have
the power or authority to bind or obligate the other except as expressly set
forth in this Agreement.

     11.14 Accrued Rights; Surviving Obligations. Unless explicitly provided
otherwise in this Agreement, termination, relinquishment or expiration of this
Agreement for any reason shall be without prejudice to any rights, which shall
have accrued to the benefit to any Party prior to such termination,
relinquishment or expiration, including damages arising from any breach
hereunder. Such termination, relinquishment or expiration shall not relieve any
Party from obligations which are expressly indicated to survive termination or
expiration of the Agreement, including, without limitation, those obligations
set forth in Sections 3.7 (relating to adverse event reporting), 5.6 (relating
to maintenance of records; audit), 7.1 (relating to confidentiality), 7.3
(relating to confidentiality), 9.5 (relating to effect of expiration or
termination), 10.1 (relating to ownership of technology and patent rights), 11.4
(relating to notices), 11.9 (relating to governing law), 11.10 (relating to
nature of licenses), 11.16 (relating to expenses) and 11.17 (relating to third
party beneficiaries) and Articles 6 (relating to representations and warranties)
and 8 (relating to indemnification) hereof.

     11.15 Compliance with Export Regulations. None of the Parties shall export
any technology licensed to it by the other Party under this Agreement, except in
compliance with United States export laws and regulations.

     11.16 Expenses. Unless otherwise provided herein, all costs and expenses
incurred in connection with this Agreement and the transactions contemplated
hereby shall be paid by the Party which shall have incurred the same and the
other Party shall have no liability relating thereto.

     11.17 No Third Party Beneficiaries. No person or entity other than the
Parties hereto and their respective Affiliates, successors and permitted assigns
shall be deemed an intended beneficiary hereunder or have any right to enforce
any obligation of this Agreement.

     11.18 No Strict Construction. This Agreement has been prepared jointly and
shall not be strictly construed against either Party.

                      [SIGNATURE PAGE IMMEDIATELY FOLLOWS]

                                      -34-
<PAGE>
     IN WITNESS WHEREOF, duly authorized representatives of the Parties have
duly executed this Agreement as of the Effective Date.

                                        EPICEPT CORPORATION

                                        By: /s/ JOHN V. TALLEY
                                            ------------------------------------
                                            Name: John V. Talley
                                            Title: Chief Executive Officer

                                        ENDO PHARMACEUTICALS INC.

                                        By: /s/ CAROL A. AMMON
                                            ------------------------------------
                                            Name: Carol A. Ammon
                                            Title: Chairman and CEO

                       SIGNATURE PAGE TO LICENSE AGREEMENT
<PAGE>
                                  Schedule 1.16

                            EpiCept Licensed Patents

<TABLE>
<CAPTION>
                               Application No./                                   Inventor(s)/
Patent Title                      Patent No.          Country      Filing Date      Assignee
----------------------------   ----------------   --------------   -----------   --------------
<S>                            <C>                <C>              <C>           <C>
Method and Composition for     US 5,776,952       US                             Liedtke/
Topical Therapy of Back Pain                                                     EpiCept
and Muscle Tension             EP 96 111 436.0    Europe:
                               EP 0 758 548 B1    Germany
                                                  France
                                                  Italy
                                                  Netherlands
                                                  Spain
                                                  Sweden
                                                  United Kingdom

Intradermal-Penetration                           US                 9/24/02     Fischer et al/
Agents for Topical Local       09/523,652         US                 3/10/00     EpiCept
Anesthetic Administration      6,455,066          US                 3/6/01
                               PCT/US01/07060     PCT                3/9/01

                               P 01 01 01125      Argentina          3/6/01
                                                  Brazil             3/9/01
                               No. 536-2001       Chile              3/6/01
                               No. 01809238.1     China              3/6/01
                               PV 2002-3030       Czech Rep.         3/6/01
                               No. 01918363.1     European
                                                  Hungary
                                                  India
                                                  Israel             3/6/01
                               No. 13-566701      Japan              3/6/01
                               No. 2002-7011879   Korea              3/6/01

                               No. 2002/008828    Mexico
                                                  New Zealand        3/6/01
                               No. 20024309       Norway             3/8/01
                               No. 1-2001-00573   Philippines
                                                  Poland
                                                  Russia
                                                  Singapore
                                                  Slovak             3/9/01
                               No. 090105562      Taiwan             3/7/01
                               No. 064112         Thailand
                               No. 2001-000505    Venezuela

Intradermal Penetration        No. 10/201,901     US                 7/25/02     Fischer, Huber,
Agents for Topical Local       (Continuation of                                  Mason/ EpiCept
Anesthetic Administration      09/523,652)
</TABLE>
<PAGE>
                                  Schedule 1.20

                               EpiCept Trademarks

1.   LidoPAIN(R)

2.   EpiCept(TM)
<PAGE>
                                  Schedule 4.1

                        EpiCept Wire Transfer Instruction

***
<PAGE>
                                 Schedule 6.2(f)

                          EpiCept Third Party Consents

     There are no Third Party Consents required.
<PAGE>
                               Schedule 6.2(g)(i)

                   Regulatory Status of LidoPAIN(R) BP Product

1.   US IND #60,957

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]